

GRANTS AND BURSARIES							
APRIL 1, 2014 - MARCH 31, 2015							
	NAME	AGENCY	TITLE	External Grants	Career Awards	Industrial Contracts	Clinical Research Awards
			JGH Totals (External grants & career awards)	39,075,596	5,743,324	5,124,688	
Students			Medicine Totals (External grants & career awards)	27,568,152	2,927,850	4,174,821	188,000
	Operating Grants & Awards		Medicine - Totals	27,568,152	2,927,850	4,174,821	188,000
	AFILALO, Jonathan	Fondation des maladies du coeur du Canada (FMCC)	Measurements of frailty to identify high-risk elderly patients referred for surgical and transcatheter aortic valve replacement.		11,126		
	AFILALO, Jonathan	Fonds de la recherche en santé du Québec (FRSQ)	Mesure de la fragilité pour identifier les patients âgés à haut risque de complications après un remplacement valvulaire aortique chirurgical ou percutané		22,778		
	AFILALO, Jonathan	Fonds de la recherche en santé du Québec (FRSQ)	Mesure de la fragilité pour identifier les patients âgés à haut risque de complications après un remplacement valvulaire aortique chirurgical ou percutané	1,236			
	AFILALO, Jonathan	Fonds de la recherche en santé du Québec (FRSQ)	Mesure de la fragilité pour identifier les patients âgés à haut risque de complications après un remplacement valvulaire aortique chirurgical ou percutané	7,527			
	AFILALO, Jonathan	Instituts de recherche en santé du Canada (IRSC)	Measurement of frailty to identify high-risk elderly patients referred for surgical and transcatheter aortic valve replacement	91,626			
	AFILALO, Marc	Fonds de la recherche en santé du Québec (FRSQ)	Utilisation des services médicaux d'urgence et hospitaliers chez la clientèle âgée de 75 ans et plus : Quel est l'impact de l'accès aux ressources médicales et communautaires de première ligne ?	1,598			
	AFILALO, Marc	Regroupement de particuliers	Emergency Department Research.	510,706			
	AGULNIK, Jason	Jewish Hospital Foundation	LunGevity Pulmonary Oncology Research.	90,317			
Morand, Grégoire	ALAOUI-JAMALI, Moulay	Recherche suisse contre le cancer (RSC)	Identifying novel markers of oral cancer progression.		5,806		
Merchavy, Shlomo	ALAOUI-JAMALI, Moulay	Crown Family Philanthropies	Research of exosomes in tongue cancer.		20,604		
Morand, Grégoire	ALAOUI-JAMALI, Moulay	Recherche suisse contre le cancer (RSC)	Identifying novel markers of oral cancer progression.		24,153		
Alkailani, Maisa Ismael GH	ALAOUI-JAMALI, Moulay	Qatar National Research Fund (QNRF)	Investigation of Novel Therapeutic Targets for Inflammatory Breast Cancer		50,545		
Alkailani, Maisa Ismael GH	ALAOUI-JAMALI, Moulay	Qatar National Research Fund (QNRF)	Investigation of Novel Therapeutic Targets for Inflammatory Breast Cancer		55,861		
	ALAOUI-JAMALI, Moulay	Fondation du cancer du sein du Québec	Études précliniques de molécules anti-métastatiques capables de re-programmer des cellules invasives du cancer du sein exprimant des marqueurs EMT/cellules souches.	30,907			
	ALAOUI-JAMALI, Moulay	Société de recherche sur le cancer Inc	Optimization of novel therapeutic approach targeting breast cancer cell plasticity and epithelial-to-mesenchymal transition for metastatic breast cancer.	112,912			
	ALAOUI-JAMALI, Moulay	Instituts de recherche en santé du Canada (IRSC)	Investigation of the filamin signaling network's function in cancer progression.	140,132			
	ASSOULINE, Sarit	Fonds de la recherche en santé du Québec (FRSQ)	Des interventions pharmacologiques innovantes ciblant la transcription et la traduction génique entraîneront des réponses significatives dans le traitement des tumeurs lympho-myéloïdes malignes : proposition de deux essais cliniques, qui font le pont entr		8,940		
CHU, Tsz Wai	AUTEXIER, Chantal	Université McGill	Characterization of the insertion finger domain of telomerase.		956		
MANCINI, Johanna	AUTEXIER, Chantal	Fondation Cole	Telomerase associated proteins		5,440		
MacNeil, Deanna	AUTEXIER, Chantal	Université McGill	Telomerase regulation by sumoylation.		8,154		
MANCINI, Johanna	AUTEXIER, Chantal	Fondation Cole	Telomerase associated proteins		16,560		
CHU, Tsz Wai	AUTEXIER, Chantal	Fonds de la recherche en santé du Québec (FRSQ)	Caractérisation d'un domaine unique (Insertion in Fingers Domain) de la transcriptase inverse télomérase dans le maintien des télomères, la survie cellulaire et son implication dans la maladie de la dyskératose congénitale.		18,407		
GOLABI, Nahid	AUTEXIER, Chantal	Fonds de la recherche en santé du Québec (FRSQ)	Caractérisation des mécanismes contrôlant la recombinaison télomérique et la survie des cellules cancéreuses		20,000		
	AUTEXIER, Chantal	Instituts de recherche en santé du Canada (IRSC)	2nd Canadian Symposium on Telomeres and Genome Integrity	3,813			
	AUTEXIER, Chantal	Institut de recherche de la Société canadienne du Cancer (IRSCC)	A haploid genetic screen in human cells to identify genes regulating chromosome end protection.	16,209			
	AUTEXIER, Chantal	Université McGill	Telomerase regulation.	32,212			
	AUTEXIER, Chantal	Instituts de recherche en santé du Canada (IRSC)	Telomerase regulation.	133,429			

	BARON, Murray	Regroupement de compagnies, corporations	A multicenter, open label study to describe the safety of daily subcutaneous injections of Anakinar (r-metHuL-1ra) in patients with rheumatoid arthritis.	56,170		
	BARON, Murray	Regroupement de compagnies, fondations et particuliers (Canada)	Canadian Scleroderma Research Group.	60,450		
	BATIST, Gerald	Fonds de la recherche en santé du Québec (FRSQ)	Axe thérapies expérimentales / Réseau de recherche sur le cancer	3,163		
	BATIST, Gerald	Sir Mortimer B. Davis - Hôpital Général Juif	2009 Ride to Conquer Cancer	21,000		
	BATIST, Gerald	Princess Margaret Hospital Foundation (The)	Ride 2009, 2010 Royalty Collaborative Research.	35,000		
	BATIST, Gerald	Research Foundation Sir Mortimer B. Davis, Jewish General Hospital	Segal Research Coordination	100,000		
	BATIST, Gerald	Hoffmann-La Roche Limitée, Canada	WINTHER Trial - WIN (Worldwid Innovative Network: For Personalized Medicine.	100,000		
	BATIST, Gerald	Instituts de recherche en santé du Canada (IRSC)	Novel strategy to selectively target tumor cell growth and chemosensitivity.	153,556		
	BATIST, Gerald	Regroupement de particuliers	Translational Research Center.	157,368		
	BATIST, Gerald	Consortium de recherche en oncologie clinique (Q-CROC)	(Q-CROC-01) - PMPC - Projet mobilisateur: Partenariat pour la médecine personnalisée en cancer du Québec.	645,967		
	BATIST, Gerald	Génome Québec	Réseau en soins de santé personnalisés Q-CROC.	721,052		
	BATIST, Gerald	Institut de recherche Terry Fox (IRTF)	Pan-Canadian colorectal cancer consortium (C4) - phase I.	1,101,794		
	BATIST, Gerald	Regroupement de particuliers	Oncology Research.	1,765,807		
NEGOITA, Bogdan	BELAND, François	Fonds de recherche du Québec - Société et culture (FRQSC)	Technology use and knowledge transfer.		797	
Lepage, Annick	BELAND, François	École nationale d'administration publique (ÉNAP)	L'évolution conjointe du professionnalisme et de l'organisation des soins dans le contexte du Centre Segal sur le cancer.		4,368	
Tsujimoto, Masashi	BELAND, François	National Center for Geriatrics and Gerontology (The) (NCGG)	The methodology comparison of longitudinal study between Canada and Japan.		8,820	
	BELAND, François	Instituts de recherche en santé du Canada (IRSC)	Veillissement et les maladies chroniques de RUIS McGill (Réseau Universitaire Intégré de Santé McGill).	284		
	BELAND, François	Instituts de recherche en santé du Canada (IRSC)	Canadian Longitudinal Study on Aging (CLSA) - Mobility Initiative (CMI) An Emerging Team in Mobility in Aging	371		
	BELAND, François	Université de Montréal	Évaluation des interventions individuelles et sociétales pour promouvoir le vieillissement actif	696		
	BERGMAN, Howard	Instituts de recherche en santé du Canada (IRSC)	Canadian Longitudinal Study on Aging (CLSA) - Mobility Initiative (CMI) An Emerging Team in Mobility in Aging	1,238		
	BERGMAN, Howard	Fonds de recherche du Québec - Santé (FRQS)	Plan d'action ministériel sur les troubles cognitifs liés au vieillissement: une évaluation de l'implantation et des résultats des projets initiaux en vue d'une généralisation progressive au Québec.	9,693		
	BERGMAN, Howard	Instituts de recherche en santé du Canada (IRSC)	Assessing care models implemented in primary health care for persons with Alzheimer's disease and related disorders	45,499		
	BERGMAN, Howard	Instituts de recherche en santé du Canada (IRSC)	Canadian Longitudinal Study on Aging (CLSA) ou Étude longitudinale canadienne sur le vieillissement (ELCV) suite du projet 41901	65,300		
	BERGMAN, Howard	Instituts de recherche en santé du Canada (IRSC)	Canadian Consortium on Neurodegeneration in Aging - Full Proposal	194,964		
MEHDI, Tahiri	BERGMAN, Simon	Université McGill	Understanding surgical recovery in elderly patients and its association with quality care.		15,055	
	BERGMAN, Simon	Fonds de la recherche en santé du Québec (FRSQ)	Optimisation de la qualité des soins et du rétablissement chirurgical chez les personnes âgées		25,374	
	BERGMAN, Simon	Research Foundation Sir Mortimer B. Davis, Jewish General Hospital	Surgical research.	8,000		
	BERGMAN, Simon	Hôpital Saint Mary's, Montréal	Understanding the association between perioperative recovery process-based quality indicators and surgical recovery in the elderly.	22,600		
	BERGMAN, Simon	Instituts de recherche en santé du Canada (IRSC)	Assessing care models implemented in primary health care for persons with Alzheimer's disease and related disorders	38,999		
	BERGMAN, Simon	Instituts de recherche en santé du Canada (IRSC)	Understanding surgical recovery in elderly patients and its association with quality of care.	212,214		
Saliba, James	BLANK, Volker	Société d'entreprise et de gestion (SEG) (Liban)	Role of CNC and Maf transcription in mammalian gene regulation, stress response and tumorigenesis.		2,102	
DODARD-FRIEDMAN, Isadore	BLANK, Volker	Université McGill	The role of the NFE2L3 transcription factor in breast cancer.		5,011	
KANNAN, Meenakshi Bhairavi	BLANK, Volker	Université McGill	Role of Nrf3 transcription factor in carcinogenesis.		6,989	

BURY, Marina	BLANK, Volker	Université McGill	Role of the transcription factor NFE 2L3 in cellular stress response and tumorigenesis.		15,055		
	BLANK, Volker	Société canadienne du Cancer	Novel regulatory pathways controlling hematopoietic stem cell fate.		14,881		
	BLANK, Volker	Société canadienne du Cancer	Novel regulatory pathways controlling hematopoietic stem cell fate.		83,791		
	BLANK, Volker	Fondation du cancer du sein du Québec	Contrôle de l'invasion de cellules de sein cancéreuses par des facteurs de transcription de type CNC.		86,302		
	BLANK, Volker	Instituts de recherche en santé du Canada (IRSC)	Regulation and function of NFE2L3: Linking transcription factor activity to carcinogenesis.		136,772		
	BLOSTEIN, Mark	Fondation des Maladies du Coeur du Québec	Prospective cohort study on the safety of peri-operative management of dabigatran.		2,139		
	BLOSTEIN, Mark	Bayer Canada Inc.	Treatment of DVT, PE and SPAF.		22,000		
	BLOSTEIN, Mark	Instituts de recherche en santé du Canada (IRSC)	Pharmacogenomic Study of Warfarin.		25,000		
	BLOSTEIN, Mark	Fondation des maladies du coeur du Canada (FMCC)	Role of gas6 and inflammation in the pathophysiology of venous thromboembolism.		33,874		
	BLOSTEIN, Mark	Instituts de recherche en santé du Canada (IRSC)	Plane-wave quantitative ultrasound imaging of blood mechanical properties		34,849		
	BLOSTEIN, Mark	National Institutes of Health (NIH) (USA)	U01HL087229 - Bridging anticoagulation in patients who Require temporary Interruption of warfarin therapy for an elective invasive procedure or surGEry(BRIDGE) trial.		37,866		
	BLOSTEIN, Mark	Fondation des maladies du coeur du Canada (FMCC)	Role of gas6 and inflammation in the pathophysiology of venous thromboembolism.		104,255		
	BORCHERS, Christoph	Université McGill	The Segal McGill Chair in Molecular Oncology at McGill University and the Jewish General Hospital.		7,418		
	BORCHERS, Christoph	Université McGill	The Segal McGill Chair in Molecular Oncology at McGill University and the Jewish General Hospital.		15,082		
	BORCHERS, Christoph	Université McGill	The Segal McGill Chair in Molecular Oncology at McGill University and the Jewish General Hospital.		4,932		
	BORCHERS, Christoph	Sir Mortimer B. Davis - Hôpital Général Juif	The Segal McGill Chair in Molecular Oncology at McGill University and the Jewish General Hospital.		14,178		
	BORCHERS, Christoph	Université McGill	The Segal McGill Chair in Molecular Oncology at McGill University and the Jewish General Hospital.		15,034		
	BORCHERS, Christoph	Sir Mortimer B. Davis - Hôpital Général Juif	The Segal McGill Chair in Molecular Oncology at McGill University and the Jewish General Hospital.		43,224		
	BOUROS, Marylise	Institut de Recherche du Centre Universitaire de Santé de McGill	Natural history of diverticular abscess managed with non-operative intent.		4,000		
	CHALIFOUR, Lorraine	Fondation des Maladies du Coeur du Québec	Endocrine disruptor re-programming of the heart: mechanism and implications for the progression to disease.		7,418		
	CHEN-TOURNOUX, Annabel	Instituts de recherche en santé du Canada (IRSC)	MITNEC B5: Non-isotope based imaging modalities vs 99mTc SPECT myocardial perfusion imaging (MPI) to detect myocardial ischemia in patients at high risk for ischemic cardiovascular events.		8,562		
RONCERO, Carlos	CHERTKOW, Howard	Société Alzheimer du Canada	Anomia in Alzheimer's disease: what causes an inability to name objects and how could the situation be improved?		17,330		
RONCERO, Carlos	CHERTKOW, Howard	Société Alzheimer du Canada	Anomia in Alzheimer's disease: what causes an inability to name objects and how could the situation be improved?		24,170		
	CHERTKOW, Howard	Société Parkinson Canada	Comparing the nature and evolution of Mild Cognitive Impairment in individuals with and without Parkinson's disease		1,250		
	CHERTKOW, Howard	Instituts de recherche en santé du Canada (IRSC)	Comparing the nature and evolution of Mild Cognitive Impairment in individuals with and without Parkinson's disease		7,535		
	CHERTKOW, Howard	Fonds de la recherche en santé du Québec (FRSQ)	Consortium pour l'identification précoce de la Maladie d'Alzheimer - Québec (CIMA-Q).		8,332		
	CHERTKOW, Howard	Instituts de recherche en santé du Canada (IRSC)	Canadian Consortium on Neurodegeneration in Aging.		10,440		
	CHERTKOW, Howard	Instituts de recherche en santé du Canada (IRSC)	CCNA Agreement 1393: KT activities carried out by the CCNA knowledge transfer cross-cutting program CCP. (Dalhousie University, Halifax, Nova Scotia - Ken Rockwood)		15,000		
	CHERTKOW, Howard	Instituts de recherche en santé du Canada (IRSC)	H. Chertkow-Expression of interest for CCNA.		17,705		
	CHERTKOW, Howard	Instituts de recherche en santé du Canada (IRSC)	CCNA Agreement 1391: Issues in rural dementia care. (University of Saskatchewan, Saskatoon, College of Nursing, Saskatoon, Saskatchewan -Debra Morgan).		25,000		
	CHERTKOW, Howard	Alberta Prion Research Institute-Alberta Ingenuity	CCNA Agreement 1388: Protein misfolding, sub-project 3D. (The Alberta Innovates - Bio Solutions (AI-Bio) - The Alberta Prion Research Institute (APRI) - Andriy Kolavenko)		30,000		

	CHERTKOW, Howard	Instituts de recherche en santé du Canada (IRSC)	The impact of beta-amyloid burden on cognition in normal aging.	36,429		
	CHERTKOW, Howard	Instituts de recherche en santé du Canada (IRSC)	Assessing care models implemented in primary health care for persons with Alzheimer's disease and related disorders	38,999		
	CHERTKOW, Howard	Fonds de la recherche en santé du Québec (FRSQ)	Entre le laboratoire et le chevet : validation de bio-marqueurs optimisés par résonance magnétique pour le diagnostic clinique précoce et le pronostic dans la maladie d'Alzheimer.	49,984		
	CHERTKOW, Howard	Instituts de recherche en santé du Canada (IRSC)	Alzheimer's disease cooperative study - project #1.	60,000		
	CHERTKOW, Howard	National Institutes of Health (NIH) (USA)	Clinical assessment of patients with AD and NEC individuals.	89,774		
	CHERTKOW, Howard	Weston Brain Institute	Development and validation of tau protein in saliva as an indicator for early Alzheimer's Disease.	112,720		
	CHERTKOW, Howard	Instituts de recherche en santé du Canada (IRSC)	Anomia in Alzheimer's Disease: Untangling semantic components and delivering therapy with rTMS.	153,303		
	CHERTKOW, Howard	Regroupement de particuliers	Alzheimer's Research.	286,562		
	CHERTKOW, Howard	Instituts de recherche en santé du Canada (IRSC)	Canadian Consortium on Neurodegeneration in Aging - Full Proposal	2,526,092		
	COHEN, Albert	QUEEN'S UNIVERSITY	Integrating a quality of life assessment and practice support system in palliative homecare.	4,242		
	COHEN, Albert	Regroupement de particuliers	Inflammatory bowel disease.	36,440		
PENNER, Jamie	COHEN, S Robin	Instituts de recherche en santé du Canada (IRSC)	Development and feasibility testing of a home-based physical activity intervention for family caregivers of people with advanced cancer.		4,167	
LAFOREST, Esther	COHEN, S Robin	Université McGill	Exploring the implementation of a provisional program to train nurse champions in a cardiac palliative approach.		11,831	
BEAUCHEMIN, Antoine	COHEN, S Robin	Instituts de recherche en santé du Canada (IRSC)	Exploring how advanced cancer patients experience high or low existential well-being: A mixed-methods study.		19,992	
	COHEN, S Robin	Réseaux de centres d'excellence du Canada (RCE)	Integrating quality of life assessments into acute care for older adults with chronic life-limiting illness.	5,436		
	COHEN, S Robin	Max Bell Foundation	Caring for the caregiver: Implementation of an evidence-based novel service for family caregivers of cancer patients at the end of life	31,495		
Lu, Chang	EISENBERG, Mark	Université McGill	The safety and efficacy of ABSORB bioresorbable vascular scaffold: A systematic review.		1,000	
Touma, Lahoud	EISENBERG, Mark	Instituts de recherche en santé du Canada (IRSC)	Apixaban and the risk of bleeding: a meta-analysis of randomized controlled trials.		2,834	
Harel-Sterling, Lee	EISENBERG, Mark	Université McGill	Pharmacological options for stroke prevention among patients undergoing trans-aortic valve implantation (TAVI).		3,125	
GRANDI, Sonia	EISENBERG, Mark	Instituts de recherche en santé du Canada (IRSC)	A population-based analysis of the trends in treatment and management of patients with acute myocardial infarction complicated by cardiogenic shock.		35,000	
	EISENBERG, Mark	Instituts de recherche en santé du Canada (IRSC)	Hypertensive Disorders in Pregnancy and the Risk of Subsequent Cardiovascular Disease		35,000	
	EISENBERG, Mark	Instituts de recherche en santé du Canada (IRSC)	Optimizing physician training in motivational communication (MC) skills for health behavior change	4,339		
	EISENBERG, Mark	Instituts de recherche en santé du Canada (IRSC)	Optimizing physician training in motivational interviewing (MI) to improve MI competency, patient health behaviors, and morbidity among patients with cardiovascular and chronic lung disease	4,540		
	EISENBERG, Mark	Instituts de recherche en santé du Canada (IRSC)	Population Level Evaluation of Ablation Therapies in Atrial Fibrillation	17,211		
	EISENBERG, Mark	Instituts de recherche en santé du Canada (IRSC)	The efficacy and safety of smoking cessation interventions in patients with cardiovascular disease: A meta-analysis of randomized controlled trials.	49,980		
	EISENBERG, Mark	Instituts de recherche en santé du Canada (IRSC)	The clinical, regulatory, and ethical implications of electronic cigarettes: A knowledge synthesis grant.	91,484		
	EISENBERG, Mark	Instituts de recherche en santé du Canada (IRSC)	Evaluating the efficacy of E-cigarette use for smoking cessation (E3) trial.	161,604		
	ERNST, Pierre-Paul	Instituts de recherche en santé du Canada (IRSC)	CIHR - Quebec Respiratory Health Training Program	8,125		
	ERNST, Pierre-Paul	Instituts de recherche en santé du Canada (IRSC)	The impact of a brief motivational intervention on adherence behavior in asthmatics: A randomized controlled trial	11,783		
Vincent, Sophie	FILION, Kristian	Université McGill	Long-term outcomes for stenting versus endarterectomy for carotid stenosis: A meta-analysis of randomized controlled trials.		2,000	
Vincent, Sophie	FILION, Kristian	Instituts de recherche en santé du Canada (IRSC)	Long-term outcomes for stenting versus endarterectomy for carotid stenosis: A meta-analysis of randomized controlled trials.		2,834	

	FILION, Kristian	Instituts de recherche en santé du Canada (IRSC)	The cardiovascular safety of varenicline: A population-based cohort study.		60,000		
	FILION, Kristian	Fonds de la recherche en santé du Québec (FRSQ)	Une évaluation populationnelle des effets cardiovasculaires indésirables des médicaments	3,709			
	FILION, Kristian	Fonds de la recherche en santé du Québec (FRSQ)	Une évaluation populationnelle des effets cardiovasculaires indésirables des médicaments	11,291			
	FILION, Kristian	Instituts de recherche en santé du Canada (IRSC)	A population-based assessment of the cardiovascular effects of 5-alpha reductase inhibitors.	59,384			
WU, Mona	FOULKES, William David	Research Foundation Sir Mortimer B. Davis, Jewish General Hospital	DICER1 mutations occurring in childhood anaplastic sarcoma of kidney.		146		
WITKOWSKI, Leora	FOULKES, William David	Sir Mortimer B. Davis - Hôpital Général Juif	New cases of small cell carcinoma of the ovary, hypercalcemic type (SCCOHT).		500		
WITKOWSKI, Leora	FOULKES, William David	Société canadienne du Cancer	AAO Annual Meeting 2014.		850		
WU, Mona	FOULKES, William David	Université McGill	Towards creation of a dilier plezotropic tumour predisposition cell model.		1,000		
Di Iorio, Massimo	FOULKES, William David	Université McGill	Deciphering the role of deep-intronic variants in mutation negative DICER1-associated phenotypes.		1,000		
WITKOWSKI, Leora	FOULKES, William David	Fonds de la recherche en santé du Québec (FRSQ)	Facteurs Génétiques du Cancer de l'Ovaire Non-Épithéliale		1,236		
	FOULKES, William David	Université McGill	James McGill Professorship Award.		1,236		
Rivera Polo, Barbara	FOULKES, William David	Ministère de l'Éducation, du Loisir et du Sport (MELS) (Québec)	1)Characterization of rare variants in hereditary colorectal syndromes. 2) Dicer1, microRNA and childhood cancer.		3,654		
	FOULKES, William David	Université McGill	James McGill Professorship Award.		3,764		
De Kock, Leanne	FOULKES, William David	Université McGill	DICER Research.		3,786		
WU, Mona	FOULKES, William David	Fonds de la recherche en santé du Québec (FRSQ)	In vitro modelling of DICER1-linked tumours		4,176		
Rivera Polo, Barbara	FOULKES, William David	Fundación Alfonso Martín Escudero	1)Characterization of rare variants in hereditary colorectal syndromes. 2) Dicer1, microRNA and childhood cancer.		5,208		
ZAYED, Nadia	FOULKES, William David	Université McGill	Susceptibilité génétique au cancer du sein dans la population canadienne québécoise.		7,418		
WITKOWSKI, Leora	FOULKES, William David	Fonds de la recherche en santé du Québec (FRSQ)	Recherche des mutations causales dans les tumeurs rares de l'ovaire.		8,352		
Rivera Polo, Barbara	FOULKES, William David	Fundación Alfonso Martín Escudero	1)Characterization of rare variants in hereditary colorectal syndromes. 2) Dicer1, microRNA and childhood cancer.		17,495		
	FOULKES, William David	Génome Canada	Personalised risk stratification for prevention and early detection of breast cancer.	101			
	FOULKES, William David	Fonds de la recherche en santé du Québec (FRSQ)	Simulation du coût/efficacité et du coût/utilité du dépistage des gènes de prédisposition au cancer du sein	244			
	FOULKES, William David	Instituts de recherche en santé du Canada (IRSC)	A research and knowledge network on genetic health services and policy: building on the APOGEE-Net and CanGeneTest experiences.	245			
	FOULKES, William David	Génome Canada	Personalised risk stratification for prevention and early detection of breast cancer.	351			
	FOULKES, William David	Génome Canada	Personalised risk stratification for prevention and early detection of breast cancer.	812			
	FOULKES, William David	Génome Canada	Personalised risk stratification for prevention and early detection of breast cancer.	1,003			
	FOULKES, William David	National Institutes of Health (NIH) (USA)	PROSTATE CANCER SUSCEPTIBILITY: THE ICPCG STUDY	1,061			
	FOULKES, William David	Ministère des relations internationales du Québec	Identification de nouveaux gènes de susceptibilité à la néoplasie colorectale	1,230			
	FOULKES, William David	Université McGill	James McGill Professorship Award.	1,854			
	FOULKES, William David	Société canadienne du Cancer	Nomination for the Canadian Cancer Society's O. Harold Warwick Prize in Cancer Control Research	2,500			
	FOULKES, William David	Génome Canada	Personalised risk stratification for prevention and early detection of breast cancer.	2,942			
	FOULKES, William David	Génome Canada	Personalised risk stratification for prevention and early detection of breast cancer.	3,125			
	FOULKES, William David	Génome Canada	Personalised risk stratification for prevention and early detection of breast cancer.	3,742			
	FOULKES, William David	Alliance canadienne pour la recherche sur le cancer du sein	Risk factor analysis of hereditary breast and ovarian cancer	4,604			
	FOULKES, William David	Ministère de l'enseignement supérieur, de la recherche, de la science et de la technologie (MESRST)	Identification de nouveaux gènes de susceptibilité à la néoplasie colorectale	4,833			

	FOULKES, William David	Ministère de l'enseignement supérieur, de la recherche, de la science et de la technologie (MESRST)	Identification de nouveaux gènes de susceptibilité à la néoplasie colorectale	5,501		
	FOULKES, William David	Université McGill	James McGill Professorship Award.	5,646		
	FOULKES, William David	Commission Européenne	Identification of new colorectal cancer susceptibility genes	6,355		
	FOULKES, William David	Merck Sharp & Dohme Research Laboratory	Genome-wide approach to dissect driver pathways in small cell carcinoma of the ovary, hypercalcaemic type	8,288		
	FOULKES, William David	Fondation du cancer du sein du Québec	Axe banque de tissus et de données BTD / Réseau de recherche sur le cancer / projet "Tumeurs sein / ovaire 26380	8,750		
	FOULKES, William David	Fonds de la recherche en santé du Québec (FRSQ)	Axe banque de tissus et de données BTD / Réseau de recherche sur le cancer / projet "Tumeurs sein / ovaire 26380	8,755		
	FOULKES, William David	Fondation du cancer du sein du Québec	Pratiques de dépistage du cancer des non-porteuses de mutations familiales des gènes BRCA1/2: Étendue, déterminants et impact psychosocial du sur-dépistage	9,523		
	FOULKES, William David	Ministère de l'enseignement supérieur, de la recherche, de la science et de la technologie (MESRST)	Identification de nouveaux gènes de susceptibilité à la néoplasie colorectale	9,824		
	FOULKES, William David	Fondation du cancer du sein du Québec	La génétique du cancer du sein dans la population québécoise : vingt ans après BRCA1/2	11,676		
	FOULKES, William David	Regroupement de particuliers	Surgical Research.	13,489		
	FOULKES, William David	Alex's Lemonade Stand Foundation (USA)	DICER1 , microRNAs and pediatric cancer: an emerging story	15,453		
	FOULKES, William David	Institut de recherche de la Société canadienne du Cancer (IRSCC)	DICER1 and pituitary blastoma: Keys to understanding pituitary development and tumorigenesis.	16,621		
	FOULKES, William David	Institut de recherche de la Société canadienne du Cancer (IRSCC)	Towards a biological understanding of small cell carcinoma of the ovary, hypercalcaemic type.	16,690		
	FOULKES, William David	Institut de recherche de la Société canadienne du Cancer (IRSCC)	DICER1 and pituitary blastoma: Keys to understanding pituitary development and tumorigenesis.	33,379		
	FOULKES, William David	Susan G. Komen Breast Cancer Foundation (The)	hereditary Breast Cancer: Cause and Effect.	39,091		
	FOULKES, William David	Alex's Lemonade Stand Foundation (USA)	DICER1 , microRNAs and pediatric cancer: an emerging story	47,047		
	FOULKES, William David	Institut de recherche Terry Fox (IRTF)	Pan-Canadian Colorectal Cancer Consortium (C4) - Phase 1	47,775		
	FOULKES, William David	Susan G. Komen Breast Cancer Foundation (The)	hereditary Breast Cancer: Cause and Effect.	78,505		
	FRIEDMAN, Ruby	Regroupement de particuliers	Geriatric Research.	68,284		
Alpuche Lazcano, Sergio Paulo	GATIGNOL, Anne	Consejo Nacional de Ciencia y Tecnología (CONACYT) (Mexico)	Mechanisms of RNA interference and RNA Decay in cytoplasmic granules during HIV-1 replication in monocytes.		9,970	
BURUGU, Samantha	GATIGNOL, Anne	Fonds de la recherche en santé du Québec (FRSQ)	Rôle de PKR et PACT dans l'activité de l'IFN de type I sur les lymphocytes T CD4+ infectés par le VIH.		15,000	
	GATIGNOL, Anne	Instituts de recherche en santé du Canada (IRSC)	Virus-cell interactions in the regulation of HIV translation.	50,000		
	GATIGNOL, Anne	Instituts de recherche en santé du Canada (IRSC)	Virus-cell interactions in the regulation of HIV translation.	64,878		
	GATIGNOL, Anne	Instituts de recherche en santé du Canada (IRSC)	The Canadian HIV Cure Enterprise (CanCURE)	76,509		
	GATIGNOL, Anne	Instituts de recherche en santé du Canada (IRSC)	Exploring interactions between HIV and the RNA interference pathway.	96,126		
	GATIGNOL, Anne	Instituts de recherche en santé du Canada (IRSC)	Development of antisense-based small RNA agents targeting the GAG open reading frame of HIV-1 RNA for use in Gene and Drug therapy against HIV-1 infection.	159,550		
NGOMA, Alain	GREENAWAY, Christina	Université McGill	Estimating and comparing the burden of chronic hepatitis B infection in the Immigrant and the Quebec born population: A population based story.		5,824	
	GREENAWAY, Christina	Fonds de recherche du Québec - Société et culture (FRQSC)	Centre Interuniversitaire québécois de statistiques sociales	1,598		
	GREENAWAY, Christina	Instituts de recherche en santé du Canada (IRSC)	Accessibility and costs of healthcare for refugee claimants following changes to the Interim Federal Health Program	33,214		
	GREENAWAY, Christina	Instituts de recherche en santé du Canada (IRSC)	Universal childhood Varicella vaccination program: Will it protect or harm the immigrant population?	72,506		

	HILZENRAT, Nir	Regroupement de compagnies, corporations	IMPROVE - Individualized Management with Pegasys RBV Offering Viral Eradication.	3,510		
	HILZENRAT, Nir	Regroupement de compagnies, corporations	Improved care and education for patients with Hepatitis B.	196,160		
	HIRSCH, Andrew	Research Foundation Sir Mortimer B. Davis, Jewish General Hospital	Interstitial lung disease (ILD).	110,675		
	HOFFER, Leonard J.	Lotte & John Hecht Memorial Foundation	Open clinical trial to validate a short-term vitamin D loading and maintenance dose protocol in people with advanced lung cancer.	95,000		
	HUDSON, Marie	Fonds de la recherche en santé du Québec (FRSQ)	Recherches observationnelles portant sur les maladies systemiques autoimmunes rhumatismales		9,111	
	HUDSON, Marie	Fonds de la recherche en santé du Québec (FRSQ)	Recherches observationnelles portant sur les maladies systemiques autoimmunes rhumatismales		28,257	
	HUDSON, Marie	Regroupement de compagnies, fondations et particuliers (Canada)	The 1000 Canadian faces of lupus study.	1,164		
	HUDSON, Marie	Grifols Canada Ltd.	Canadian inflammatory myopathy study group.	7,527		
	HUDSON, Marie	Société de l'arthrite (La)	2013-14 TAS knowledge translation/networking.	10,000		
NASRAH, Rima	JAGOE, Robert	Université McGill	New approaches to optimizing nutritional interventions in oncology patients and cachexia.		309	
	JAGOE, Robert	Instituts de recherche en santé du Canada (IRSC)	Multimodal exercise, nutrition and anti-inflammatory treatment for palliation of cancer cachexia: The MENAC study.	43,774		
Totten, Stephanie	JOHNSON, Nathalie	Université McGill	Role of Fas mutations in chemotherapy resistant lymphomas.		1,670	
Weisstock, Christina	JOHNSON, Nathalie	Université McGill	Overcoming therapeutic resistance in FAS-mutant lymphomas.		3,125	
	JOHNSON, Nathalie	Fonds de la recherche en santé du Québec (FRSQ)	Identification de biomarqueurs de prévision des lymphomes se présentant chez les adolescents et les jeunes adultes		8,751	
Sesques, Pierre	JOHNSON, Nathalie	Agence Rhône-alpes pour les Sciences Humaines et Sociales	Elucidating the mechanism of therapeutic resistance in diffuse large B cell lymphoma.		14,042	
Sesques, Pierre	JOHNSON, Nathalie	Roche Diagnostics	Elucidating the mechanism of therapeutic resistance in diffuse large B cell lymphoma.		14,043	
Totten, Stephanie	JOHNSON, Nathalie	Instituts de recherche en santé du Canada (IRSC)	Role of Fas mutations in chemotherapy resistant lymphomas.		16,106	
	JOHNSON, Nathalie	Fonds de la recherche en santé du Québec (FRSQ)	Identification de biomarqueurs de prévision des lymphomes se présentant chez les adolescents et les jeunes adultes		27,219	
	JOHNSON, Nathalie	Fonds de la recherche en santé du Québec (FRSQ)	Identification de biomarqueurs de prévision des lymphomes se présentant chez les adolescents et les jeunes adultes	2,473		
	JOHNSON, Nathalie	Fondation Cole	Help develop the cell library of the Quebec Leukemia Cell Bank with young adult lymphoma cells.	4,121		
	JOHNSON, Nathalie	Institut de recherche de la Société canadienne du Cancer (IRSCC)	Optimizing therapy for STAT6-mutant DLBC.	8,088		
	JOHNSON, Nathalie	Sir Mortimer B. Davis - Hôpital Général Juif	Help develop the cell library of the Quebec Leukemia Cell Bank with young adult lymphoma cells.	128,864		
	JOHNSON, Nathalie	Instituts de recherche en santé du Canada (IRSC)	Overcoming therapeutic resistance in lymphoma.	149,722		
	KADER, Tina	Instituts de recherche en santé du Canada (IRSC)	The Metformin in women with type 2 diabetes in pregnancy trial ("MITY" "The Study")	770		
Cohen, Jacqueline	KAHN, Susan Rebecca	Université McGill	Antioxidant and lipid levels in relation to risk of preeclampsia and small for gestational age in a large cohort of pregnant women from Montreal, Canada.		5,011	
	KAHN, Susan Rebecca	Chaires de recherche du Canada (CRC)	Venous Thromboembolism		100,000	
	KAHN, Susan Rebecca	Instituts de recherche en santé du Canada (IRSC)	GENErVTE: Gene Gene Interactions and Recurrent Venous Thromboembolism.	210		
	KAHN, Susan Rebecca	Fondation des maladies du coeur de l'Ontario (Toronto, Ont)	P. Wells - HSFO - Development and validation of clinical prediction rules for bleeding for patients on anticoagulant therapy for venous thromboembolism.	4,195		
	KAHN, Susan Rebecca	Instituts de recherche en santé du Canada (IRSC)	A pilot study assessing feasibility of a randomized, placebo-controlled trial of low-molecular-weight-heparin for postpartum prophylaxis in women at risk of developing venous thromboembolism (pilot PROSPER trial: Postpartum Prophylaxis for PE randomized)	4,480		
	KAHN, Susan Rebecca	Instituts de recherche en santé du Canada (IRSC)	The SOX trial; Disseminating the unexpected results of a large, CIHR North American RCT of elastic compression stockings to prevent the post-thrombotic syndrome.	11,272		
	KAHN, Susan Rebecca	National Institutes of Health (NIH) (USA)	Chronic venous thrombosis: Relief with adjunctive catheter-based therapy (C-TRACT) study.	17,490		
	KAHN, Susan Rebecca	Institut de Cardiologie de Montréal (ICM)	CIHR-ICRH CDP Application Preparation.	25,000		

	KAHN, Susan Rebecca	Instituts de recherche en santé du Canada (IRSC)	Extended venous thromboembolism prophylaxis comparing rivaroxaban to aspirin following total hip and knee arthroplasty (EPCAT II)	70,400		
	KAHN, Susan Rebecca	Sanofi-Aventis (Canada)	Thrombosis Fellowship.	75,000		
	KAHN, Susan Rebecca	Instituts de recherche en santé du Canada (IRSC)	Randomized controlled trial of anticoagulation vs. placebo for a first symptomatic isolated distal deep-vein thrombosis (IDVT): The CACTUS-PTS Trial.	142,563		
	KAHN, Susan Rebecca	Pfizer Canada Inc.	Venous Thromboembolism	250,000		
Jayasundera, Thiran	KAPUSTA, Michael	Sir Mortimer B. Davis - Hôpital Général Juif	TD FELLOWSHIP - Dr. Jayasundera.		45,000	
	KARAPLIS, Andrew C.	Instituts de recherche en santé du Canada (IRSC)	PTHrP and osteoblast biology: relevance to osteoporosis	82,101		
	KAVAN, Petr	Institut de recherche de la Société canadienne du Cancer (IRSCC)	Cognitive performance and psychosocial development in young adult cancer survivors: A prospective, longitudinal study.	1,087		
	KAVAN, Petr	Regroupement de particuliers	Young adult program.	13,781		
	KLEIMAN, Lawrence C.	Instituts de recherche en santé du Canada (IRSC)	Formation of the tRNALys packaging complex in HIV-1.	74,137		
	KLEIMAN, Lawrence C.	Instituts de recherche en santé du Canada (IRSC)	Regulation of primer tRNALys3 annealing to HIV-1 genomic RNA during HIV-1 replication.	100,000		
	KLEIMAN, Simcha	Research Foundation Sir Mortimer B. Davis, Jewish General Hospital	Jewish General Hospital Anesthesia Fellowship	67,500		
CHOQUET, Karine	KLEINMAN, Claudia	Fonds de la recherche en santé du Québec (FRSQ)	Impact transcriptionnel d'une mutation dans le gène POLR3A chez un modèle souris des leucodystrophies reliées à l'ARN polymérase III		5,824	
	LANGLEBEN, David	Regroupement de particuliers	Cath lab education fund.	1,500		
	LEBLANC, Andrée	Université McGill	Molecular mechanisms of neuronal cell death.		797	
DÉRY, Marc-André	LEBLANC, Andrée	Instituts de recherche en santé du Canada (IRSC)	Role of the cytosolic prion protein in the regulation of Bax ubiquitination and its impact on cell survival.		2,576	
Lynham, Jeffrey	LEBLANC, Andrée	Université McGill	Finding effective inhibitors for Caspase-6 which is a new target in the treatment of Alzheimer's disease.		3,495	
DÉRY, Marc-André	LEBLANC, Andrée	Université McGill	Role of the cytosolic prion protein in the regulation of Bax ubiquitination and its impact on cell survival.		5,824	
PAKAVATHKUMAR, Prateep	LEBLANC, Andrée	Fonds de la recherche en santé du Québec (FRSQ)	L'étude d'inhibiteurs de la Caspase-6 in vitro et in vivo pour développer une nouvelle stratégie thérapeutique pour la maladie Alzheimer		8,280	
	LEBLANC, Andrée	Université McGill	Molecular mechanisms of neuronal cell death.		9,203	
NOEL, Anastasia	LEBLANC, Andrée	Société Alzheimer du Canada	Traumatisme craniocérébral léger à répétition: impact sur la pathologie tau et effets d'un agoniste LXR.		31,239	
	LEBLANC, Andrée	Université McGill	Molecular mechanisms of neuronal cell death.	1,195		
	LEBLANC, Andrée	Université McGill	Molecular mechanisms of neuronal cell death.	13,805		
	LEBLANC, Andrée	Fonds de la recherche en santé du Québec (FRSQ)	Nouveaux modèles de la Maladie Alzheimer dans le poisson zébré.	50,000		
	LEBLANC, Andrée	Instituts de recherche en santé du Canada (IRSC)	Regulation of prion protein expression, trafficking and function	142,177		
	LEBLANC, Andrée	Instituts de recherche en santé du Canada (IRSC)	Role of caspases in human neuronal cell death and in Alzheimer's Disease.	156,259		
	LEBLANC, Andrée	Fonds de la recherche en santé du Québec (FRSQ)	Consortium pour l'identification précoce de la Maladie d'Alzheimer - Québec (CIMA-Q).	158,316		
	LEBLANC, Andrée	Regroupement de particuliers	Alzheimer's research funds.	336,000		
SIMEONE, Stefania	LEHOUX, Stephanie	Fonds de la recherche en santé du Québec (FRSQ)	Mécanismes impliqués dans la réduction de la plaque d'athérosclérose par la contrainte de cisaillement.		1,593	
	LEHOUX, Stephanie	Chaires de recherche du Canada (CRC)	Cardiovascular Physiology.		50,000	
	LEHOUX, Stephanie	Instituts de recherche en santé du Canada (IRSC)	Potential roles of Semaphorin 3A in atherosclerosis.	124,934		
	LEHOUX, Stephanie	Instituts de recherche en santé du Canada (IRSC)	Athero-protective shear stress signalling in the vasculature	127,729		
BEITARI, Saina	LIANG, Chen	Université McGill	Identifying the interaction between HIV-1 restriction factors and nuclear pore complex.		2,912	
WANG, Yimeng	LIANG, Chen	Université McGill	Studying the anti-HIV activity of IFITM proteins.		7,863	
Liang, Zhibin	LIANG, Chen	China Scholarship Council (CSC)	Identification of anti-HIV-1 interferon-stimulated genes and mechanistic study of their antiviral activities.		15,653	
	LIANG, Chen	Instituts de recherche en santé du Canada (IRSC)	Fusion and cell entry by oncogenic sheep retroviruses.	28,792		
	LIANG, Chen	Canadian Foundation for AIDS Research (CANFAR)	Investigate the anti-HIV-1 activity of interferon-induced MxB protein.	40,000		

	LIANG, Chen	Instituts de recherche en santé du Canada (IRSC)	Studying the antiviral of bone marrow stromal cell antigen 2 and the counteracting mechanism from HIV-1 Vpu.	72,135		
	LIANG, Chen	Instituts de recherche en santé du Canada (IRSC)	Study the role of SAMHD1 in HIV-1 transmission.	75,000		
	LIANG, Chen	Instituts de recherche en santé du Canada (IRSC)	Investigate the Antu-HIV-1 activity of interferon-induced MxB protein.	100,000		
	LIANG, Chen	Instituts de recherche en santé du Canada (IRSC)	Study the antiviral function of IFITM proteins.	123,708		
Liu, Yiliu	LIN, Rongtuan	Research Foundation Sir Mortimer B. Davis, Jewish General Hospital	Regulation of STING via the RIG-1 dependent RNA sensing pathway.		582	
SZE, Alexandre	LIN, Rongtuan	Fonds de la recherche en santé du Québec (FRSQ)	Caractérisation de l'apoptose induite par les ADNs produits lors d'infections rétrovirales.		18,407	
	LIN, Rongtuan	Canadian Foundation for AIDS Research (CANFAR)	Ubiquitination promotes the survival of functional HIV-specific CD4+T CM cells in elite controllers by decreasing Bim and Puma expression.	14,835		
	LIN, Rongtuan	Cancer de la prostate Canada	Combination oncolytic virotherapy for the treatment of prostate cancer.	24,725		
	LIN, Rongtuan	Instituts de recherche en santé du Canada (IRSC)	Cross-talk between host antiviral and apoptotic signaling pathways in de novo Dengue virus infection.	56,250		
	LIN, Rongtuan	Cancer de la prostate Canada	Combination oncolytic virotherapy for the treatment of prostate cancer.	75,275		
	LIN, Rongtuan	Instituts de recherche en santé du Canada (IRSC)	Innate immunity and Hepatitis C virus infection.	87,153		
	LIN, Rongtuan	Instituts de recherche en santé du Canada (IRSC)	Oncolytic virus therapy for HTLV-1 induced adult T cell leukemia.	142,154		
	LIN, Rongtuan	Instituts de recherche en santé du Canada (IRSC)	Manipulating the RIG-1 signaling pathway to inhibit influenza virus infection.	167,623		
	LIPMAN, Mark L.	Regroupement de particuliers	Hemodialysis Research.	143,733		
	LONGTIN, Yves	Fonds de la recherche en santé du Québec (FRSQ)	- Les infections nosocomiales - Une approche globale et intégrative pour mieux comprendre et prévenir la diarrhée associée au C. difficile et améliorer l'hygiène des mains		8,334	
	LONGTIN, Yves	Fonds de la recherche en santé du Québec (FRSQ)	- Les infections nosocomiales - Une approche globale et intégrative pour mieux comprendre et prévenir la diarrhée associée au C. difficile et améliorer l'hygiène des mains		26,065	
	LONGTIN, Yves	Fonds de la recherche en santé du Québec (FRSQ)	- Les infections nosocomiales - Une approche globale et intégrative pour mieux comprendre et prévenir la diarrhée associée au C. difficile et améliorer l'hygiène des mains	2,473		
	LONGTIN, Yves	Fonds de la recherche en santé du Québec (FRSQ)	- Les infections nosocomiales - Une approche globale et intégrative pour mieux comprendre et prévenir la diarrhée associée au C. difficile et améliorer l'hygiène des mains	7,527		
	MAC NAMARA, Elizabeth	Génome Québec	Clinical implementation and outcomes evaluation of blood-based biomarkers for COPD management.	216,680		
	MAC NAMARA, Elizabeth	Génome Canada	Clinical implementation and outcomes evaluation of blood-based biomarkers for COPD management.	326,897		
Negro Silva, Luis Fernando	MANN, Koren	Université McGill	Contribution of arsenic to enhance atherosclerosis.		6,989	
Wu, Ting Hua (Joshua)	MANN, Koren	Université McGill	Tungsten-induced alteration B lymphocytes.		7,863	
Bolt, Alicia Marie	MANN, Koren	Fondation Cole	The role of Tungsten in preB Cell Leukemogenesis.		9,890	
Bolt, Alicia Marie	MANN, Koren	Fondation Cole	The role of Tungsten in preB Cell Leukemogenesis.		30,110	
LEMAIRE, Maryse	MANN, Koren	Instituts de recherche en santé du Canada (IRSC)	Mechanisms of arsenic-induced atherosclerosis.		31,250	
	MANN, Koren	Institut de recherche de la Société canadienne du Cancer (IRSCC)	Optimizing therapy for STAT6-mutant DLBC.	8,088		
	MANN, Koren	Leukemia & Lymphoma Society of Canada (The) (LLSC)	The role of mutated Ras-associating proteins in R-CHOP-resistant DLBCL.	45,165		
	MANN, Koren	Instituts de recherche en santé du Canada (IRSC)	Bone as a target for Tungsten-induced toxicities.	50,000		
	MANN, Koren	Instituts de recherche en santé du Canada (IRSC)	Mechanisms of arsenic-enhanced atherosclerosis.	154,580		
	MICHEL, Caroline	National Institutes of Health (NIH) (USA)	Phosphodiesterase Type 5 inhibition with Tadalafil changes outcomes in heart failure (PITCH-HF).	2,940		
	MICHEL, Caroline	Centre universitaire de santé McGill (CUSM)	The ACE switchback study.	7,250		
DAHABIEH, Michael	MILLER, Wilson	Université McGill	Mechanisms of drug resistance in melanoma and lymphoma cells.		635	
	MILLER, Wilson	Université McGill	McGill James		797	
PETRUCCELLI, Luca	MILLER, Wilson	Instituts de recherche en santé du Canada (IRSC)	Improving combination therapies involving histone deacetylase inhibitors and DNA methyltransferase inhibitors in hematological malignancies		883	

ZHAN, Yao	MILLER, Wilson	Université McGill	Role of eIF4E in promoting melanoma cell proliferation and maintaining acquired resistance to Vemurafenib in melanoma.		1,000	
Kaddour, Nancy	MILLER, Wilson	Université McGill	Effect of Eif4E knockdown on EMT.		1,241	
DAHABIEH, Michael	MILLER, Wilson	Université McGill	Mechanisms of drug resistance in melanoma and lymphoma cells.		1,978	
ZHAN, Yao	MILLER, Wilson	Société canadienne du Cancer	Role of eIF4E in promoting melanoma cell proliferation and maintaining acquired resistance to Vemurafenib in melanoma.		2,000	
Guo, Qianyu	MILLER, Wilson	Université McGill	Elucidate the mechanism of the increased anti-leukemic potency of darinaparsin compared to arsenic trioxide.		2,967	
DUPÉRE-RICHER, Daphné	MILLER, Wilson	Fondation Cole	Anti-cancer activity of HDAC inhibitors.		5,440	
Guo, Qianyu	MILLER, Wilson	Université McGill	Elucidate the mechanism of the increased anti-leukemic potency of darinaparsin compared to arsenic trioxide.		5,724	
Kaddour, Nancy	MILLER, Wilson	Université McGill	Effect of Eif4E knockdown on EMT.		6,989	
Guo, Qianyu	MILLER, Wilson	Fondation Cole	Elucidate the mechanism of the increased anti-leukemic potency of darinaparsin compared to arsenic trioxide.		8,657	
	MILLER, Wilson	Université McGill	McGill James		9,203	
FRIEDMANN, Jennifer Elisabeth	MILLER, Wilson	Université McGill	Sophisticated new approaches in immuno-therapy and novel targeted therapy in melanoma.		15,055	
DUPÉRE-RICHER, Daphné	MILLER, Wilson	Fondation Cole	Anti-cancer activity of HDAC inhibitors.		16,560	
DAHABIEH, Michael	MILLER, Wilson	Fonds de la recherche en santé du Québec (FRSQ)	mécanismes de résistance aux médicaments dans les hémopathies malignes		16,703	
	MILLER, Wilson	Samuel Waxman Cancer Research Foundation	Development of novel anti-cancer therapies using arsenic trioxide.	10,903		
	MILLER, Wilson	Université McGill	McGill James	15,000		
	MILLER, Wilson	Université McGill	Bridge Funding.	20,000		
	MILLER, Wilson	Société canadienne du Cancer	Functional role of eIF4E in breast tumor metastasis and epithelial-to-mesenchymal transition (EMT).	24,378		
	MILLER, Wilson	Instituts de recherche en santé du Canada (IRSC)	Molecular mechanisms of retinoids as anti-virals in respiratory virus infections	34,525		
	MILLER, Wilson	Samuel Waxman Cancer Research Foundation	Development of novel anti-cancer therapies using arsenic trioxide.	40,498		
	MILLER, Wilson	Instituts de recherche en santé du Canada (IRSC)	Targeting the eukaryotic translation factor eIF4E with ribavirin in breast cancer.	70,880		
	MILLER, Wilson	Université McGill	Rosy Cancer Network (RCN).	96,099		
	MILLER, Wilson	Instituts de recherche en santé du Canada (IRSC)	Mechanisms of response and resistance in epigenetic therapy in hematological malignancy.	145,977		
	MILLER, Wilson	Regroupement de particuliers	8th International Conference of differentiation therapy - Montreal October 3-6,1999.	162,000		
	MILLER, Wilson	Instituts de recherche en santé du Canada (IRSC)	The CIHR/FRSQ Training Program in Cancer Research at McGill	162,500		
	MONETTE, Johanne	Instituts de recherche en santé du Canada (IRSC)	RADAR : A new screening tool to improve the recognition of delirium among elder persons	1,500		
	MONETTE, Johanne	Fonds de la recherche en santé du Québec (FRSQ)	Utilisation des services médicaux d'urgence et hospitaliers chez la clientèle âgée de 75 ans et plus : Quel est l'impact de l'accès aux ressources médicales et communautaires de première ligne ?	1,598		
WRIGHT, Kathryn	MORAIS, José Antonio	Fonds de la recherche en santé du Québec (FRSQ)	L'impact de l'exercice et de la supplémentation en leucine sur le muscle squelettique de femmes âgées fragilisées avec une exploration des mécanismes justificatifs		835	
WRIGHT, Kathryn	MORAIS, José Antonio	Fonds de la recherche en santé du Québec (FRSQ)	L'impact de l'exercice et de la supplémentation en leucine sur le muscle squelettique de femmes âgées fragilisées avec une exploration des mécanismes justificatifs		1,165	
	MORAIS, José Antonio	Instituts de recherche en santé du Canada (IRSC)	Veillesment et les maladies chroniques de RUIS McGill (Réseau Universitaire Intégré de Santé McGill).	284		
	MORAIS, José Antonio	Montreal General Hospital Foundation (Can)	Helen McCall Hutchison award in geriatric medicine	495		
Seltzer, Sean	MOULAND, Andrew	Université McGill	Why HIV-1 dismantles NPCs?		1,269	
Rao, Shringar	MOULAND, Andrew	Université McGill	Studies on HIV-1 cure.		4,368	
Rao, Shringar	MOULAND, Andrew	Université McGill	Studies on HIV-1 cure.		6,698	
Alpuche Lazcano, Sergio Paulo	MOULAND, Andrew	Consejo Nacional de Ciencia y Tecnología (CONACYT) (Mexico)	Mechanisms of RNA interference and RNA Decay in cytoplasmic granules during HIV-1 replication in monocytes.		9,970	
	MOULAND, Andrew	Instituts de recherche en santé du Canada (IRSC)	The Canadian HIV Cure Enterprise (CanCURE)	63,627		
	MOULAND, Andrew	Instituts de recherche en santé du Canada (IRSC)	Understanding how the HIV-1-dependent ribonucleoprotein counters host stress responses	134,164		
	MOULAND, Andrew	Instituts de recherche en santé du Canada (IRSC)	Evading and subverting host cell machineries to ensure HIV-1 genomic RNA fate.	158,294		

Borrelli, Daniel	PANASCI, Lawrence	Université McGill	BKM120 in combination with chemotherapeutic drugs in CLL therapy.		2,000		
Sharif-Askari, Bahram	PANASCI, Lawrence	Université McGill	New formation of drugs encapsulated into DNA cage delivery system.		4,945		
	PANASCI, Lawrence	Regroupement de particuliers	Donations.		28,000		
	PANASCI, Lawrence	Conseil de Recherches en Sciences Naturelles et Génie du Canada (CRSNG)	DNA cages as a platform for efficient and selective delivery of therapeutics into tumour cells.		33,334		
	PANASCI, Lawrence	Instituts de recherche en santé du Canada (IRSC)	DNA cages as a platform for efficient and selective delivery of therapeutics into tumour cells.		66,667		
	PANTOPOULOS, Kostas	Institut de recherche de la Société canadienne du Cancer (IRSCC)	Targeting cancer by small molecule inhibitors of iron regulatory protein 2 (IRP2).		16,209		
	PANTOPOULOS, Kostas	Université McGill	Iron and metabolism research.		17,500		
	PANTOPOULOS, Kostas	Conseil de Recherches en Sciences Naturelles et Génie du Canada (CRSNG)	Iron metabolism and hepatitis C virus.		36,000		
	PANTOPOULOS, Kostas	Instituts de recherche en santé du Canada (IRSC)	Iron regulatory proteins: pathophysiological functions in metabolism and cancer.		148,200		
CHO, Chulmin	PAUDEL, Hemant	Société Alzheimer du Canada	Developmentally regulated brain protein in Alzheimer's disease: Its role in synaptic dysfunction.		5,200		
CHO, Chulmin	PAUDEL, Hemant	Société Alzheimer du Canada	Developmentally regulated brain protein in Alzheimer's disease: Its role in synaptic dysfunction.		15,830		
Jinhai, Duan	PAUDEL, Hemant	Guangdong Province Science and Technology Foundation	Examine the development of Alzheimer neuropathology in mouse model.		24,740		
	PAUDEL, Hemant	Société Alzheimer du Canada	Restoration of synapse loss in AD by replenishment of drebrin in the CNS.		18,544		
	PAUDEL, Hemant	Instituts de recherche en santé du Canada (IRSC)	Neurofibrillary pathology and amyloidogenesis in Alzheimer's disease: mechanistic insights.		130,276		
Yancu, Debbie	POLLAK, Michael	Université McGill	A study on metformin and its implications in cancer treatment.		956		
Laaribi, Haithem	POLLAK, Michael	Université McGill	Effect of LDH-A inhibition with metformin treatment in cancer.		3,225		
Ruiz-Rosado, Azucena	POLLAK, Michael	Consejo Nacional de Ciencia y Tecnología (CONACYT) (Mexico)	Dose dependent effect of metformin in 4T1 mammary carcinoma growth and phosphoprotein expression.		6,384		
	POLLAK, Michael	Société de recherche sur le cancer Inc	Development of an instrument for assessing occupational exposures in cancer case-control studies and its implication to cancers of lung, brain, ovary and colon.		5,087		
	POLLAK, Michael	Société de recherche sur le cancer Inc	Development of an instrument for assessing occupational exposures in cancer case-control studies and its implication to cancers of lung, brain, ovary and colon.		7,737		
	POLLAK, Michael	Institut de recherche de la Société canadienne du Cancer (IRSCC)	Defining the roles of systemic and direct tumour effects of biguanides to optimize treatment.		10,014		
	POLLAK, Michael	Instituts de recherche en santé du Canada (IRSC)	Defining and Applying "Oncometabolism": A team approach in understanding and translating the Warburg effect from oncogenic and tumour suppressing activities.		16,773		
	POLLAK, Michael	National Institutes of Health (NIH) (USA)	An investigation of circulating adiponectin levels and monoclonal gammopathy of undetermined significance (MGUS).		23,566		
	POLLAK, Michael	Institut de recherche Terry Fox (IRTF)	Unraveling metabolic adaptations associated with disease progression and therapeutic response in metastatic breast cancer		25,405		
	POLLAK, Michael	Regroupement de particuliers	IGF and breast cancer.		35,545		
	POLLAK, Michael	Regroupement de particuliers	Stroll - cancer screening.		39,711		
	POLLAK, Michael	National Institutes of Health (NIH) (USA)	A pooled investigation of circulating adiponectin levels and risk of multiple myeloma.		69,801		
	POLLAK, Michael	National Institutes of Health (NIH) (USA)	Nurses' health study I and II women's lifestyle validation study.		161,040		
Zidova, Zuzana	PONKA, Prem	European Union (EU) Research Directorate General	Investigation of the Role of Heme-Oxygenase I in the Erythroid Differentiation		33,045		
	PONKA, Prem	Instituts de recherche en santé du Canada (IRSC)	Chelation, mobilization and metabolism of storage iron.		117,763		
	PONKA, Prem	Instituts de recherche en santé du Canada (IRSC)	Regulation of iron metabolism and heme synthesis in erythroid cells.		133,831		
Jacob, Arthur	RICHARD, Stéphane	Université McGill	The role of monomethylarginine and symmetric dimethylarginine generated by PRMT5 and PRMT7 during the DNA damage signalling.		652		
DARBELLI, Lama	RICHARD, Stéphane	Université McGill	To identify alternatively spliced RNA targets of QKI in glial cells.		1,058		
	RICHARD, Stéphane	Université McGill	James McGill Professorship Award.		1,648		
SONG, Jingwen	RICHARD, Stéphane	Université McGill	Does the Sam68 STAR RNA binding protein regulate mTOR alternative splicing and mTOR signaling pathway? What are the roles of Sam68 in neu-oncogene-breast cancer development.		1,893		
LI, Naomi	RICHARD, Stéphane	Université McGill	To define the role of Sam68 in p53-mediated functions.		2,115		

Blanc, Roméo	RICHARD, Stéphane	Université McGill	The role of PRMTs in stem cell differentiation.		2,724	
NEAULT, Mathieu	RICHARD, Stéphane	Fonds de la recherche en santé du Québec (FRSQ)	Étude de la régulation de la signalisation du dommage à l'ADN par la méthylation d'arginine et les microARNs dans les cellules cancéreuses.		4,945	
LI, Naomi	RICHARD, Stéphane	Université McGill	To define the role of Sam68 in p53-mediated functions.		6,989	
Blanc, Roméo	RICHARD, Stéphane	Université McGill	The role of PRMTs in stem cell differentiation.		6,989	
BUENO, Murilo	RICHARD, Stéphane	Fonds de la recherche en santé du Québec (FRSQ)	L'évaluation du rôle de la Jumonji demethylase KDM2A au cours de la réponse aux dommages de l'ADN		7,500	
	RICHARD, Stéphane	Université McGill	James McGill Professorship Award.		8,352	
NEAULT, Mathieu	RICHARD, Stéphane	Fonds de la recherche en santé du Québec (FRSQ)	Étude de la régulation de la signalisation du dommage à l'ADN par la méthylation d'arginine et les microARNs dans les cellules cancéreuses.		15,055	
De Bruin, Ruben	RICHARD, Stéphane	UNIVERSITAIR MEDISCH CENTRUM (UTRECHT)	The role of he RNA-binding protein quaking in inflammation.		365,118	
	RICHARD, Stéphane	Université McGill	James McGill Professorship Award.	2,473		
	RICHARD, Stéphane	Université McGill	James McGill Professorship Award.	12,527		
	RICHARD, Stéphane	Société canadienne du Cancer	Defining the regulation of platelet-derived growth factor (PDGF) signaling by protein arginine methylation.	25,055		
	RICHARD, Stéphane	Société canadienne du Cancer	Defining the regulation of platelet-derived growth factor (PDGF) signaling by protein arginine methylation.	34,945		
	RICHARD, Stéphane	Société Canadienne de la sclérose en plaques	The role of quaking proteins in oligodendrocyte physiology and myelation.	95,000		
	RICHARD, Stéphane	Instituts de recherche en santé du Canada (IRSC)	The role of the Sam68 RNA binding protein in normal and diseased cells.	111,600		
	RICHARD, Stéphane	Instituts de recherche en santé du Canada (IRSC)	The role of post-translational modifications of MRE11 in mediating the DNA damage response.	174,669		
	RICHARD, Stéphane	Instituts de recherche en santé du Canada (IRSC)	Defining the role of protein arginine methyltransferases (PRMTs) and RGG/RG motifs in cancer in the maintenance of genomic stability.	193,592		
	RICHARDS, Brent	Fonds de la recherche en santé du Québec (FRSQ)	Des causes à la clinique : Comprendre les déterminants génétiques de la maladie commune et, ainsi, permettre l'amélioration des soins aux patients		8,334	
	RICHARDS, Brent	Société canadienne d'endocrinologie et métabolisme (SCEM)	2014 Dr. Jody Ginsberg Young Investigator Award		20,000	
	RICHARDS, Brent	Fonds de la recherche en santé du Québec (FRSQ)	Des causes à la clinique : Comprendre les déterminants génétiques de la maladie commune et, ainsi, permettre l'amélioration des soins aux patients		26,065	
MANOUSAKI, Despoina	RICHARDS, Brent	Groupe canadien d'endocrinologie pédiatrique (GCEP)	The role of rare and low-frequency genetic variation in vitamin D status.		60,000	
	RICHARDS, Brent	Université McGill	Genetic determinants of 25-Hydroxy Vitmain D Levels	1,500		
	RICHARDS, Brent	Instituts de recherche en santé du Canada (IRSC)	Full resolution metabolic disease epigenomics in human populations	8,330		
	RICHARDS, Brent	Université McGill	Type 2 diabetes, glucose and coronary heart disease, a Mendelian randomization study.	14,128		
	RICHARDS, Brent	Instituts de recherche en santé du Canada (IRSC)	Full resolution metabolic disease epigenomics in human populations	41,633		
	RICHARDS, Brent	Instituts de recherche en santé du Canada (IRSC)	Pinpointing causal variants for osteoporosis.	172,964		
Blank, Nimrod	RUDSKI, Lawrence	Israel Cancer Research Fund (ICFR)	ICRF Fellowship.		12,363	
Blank, Nimrod	RUDSKI, Lawrence	Israel Cancer Research Fund (ICFR)	ICRF Fellowship.		37,637	
Ouerd, Sofiane	SCHIFFRIN, Ernesto	Université McGill	Role of vascular smooth muscle cell PPAR-gamma in endothelin-1-induced vascular disease.		1,692	
MIAN, Muhammad Oneeb Rehman	SCHIFFRIN, Ernesto	Réseaux de centres d'excellence du Canada (RCE)	Role of T regulatory lymphocytes in adlosterone-induced hypertension		2,904	
IDRIS KHODJA, Nouredine	SCHIFFRIN, Ernesto	Société Québécoise d'hypertension artérielle	Oxidative stress mechanisms in vasculature of atherosclerotic type 1 diabetic mice.		6,181	
Trindade, Michelle	SCHIFFRIN, Ernesto	Foundation for the Coordination of Higher Education and Graduate Training (CAPES Foundation) (Brazil)	Hypertension in Vascular Biology		10,322	
Al Nashmi, Tofol	SCHIFFRIN, Ernesto	Saudi Arabian Cultural Bureau in Canada	Gene expression profile in small resistance arteries in patients with hypertension with and without nephroangiolsclerosis and its relation to small and large artery function remodeling.		10,484	
Ouerd, Sofiane	SCHIFFRIN, Ernesto	Instituts de recherche en santé du Canada (IRSC)	Role of vascular smooth muscle cell PPAR-gamma in endothelin-1-induced vascular disease.		13,173	

BARHOUMI, Tlili	SCHIFFRIN, Ernesto	Université McGill	Pathophysiology of hypertension.		15,659		
BARHOUMI, Tlili	SCHIFFRIN, Ernesto	Université McGill	Pathophysiology of hypertension.		21,841		
IDRIS KHODJA, Nouredine	SCHIFFRIN, Ernesto	Fonds de la recherche en santé du Québec (FRSQ)	L'endothéline-1, les isoformes de NOX et le stress oxydant dans l'athérosclérose associée au diabète de type 1		22,582		
	SCHIFFRIN, Ernesto	Chaires de recherche du Canada (CRC)	Hypertension and vascular research.		24,658		
COELHO, Suellen Cristina	SCHIFFRIN, Ernesto	Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) (Brazil)	Endothelin, vascular inflammation and injury, and hypertension.		25,051		
Fraulob Aquino, Julio Cesar	SCHIFFRIN, Ernesto	Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) (Brazil)	Vascular remodeling in hypertension.		38,108		
	SCHIFFRIN, Ernesto	Chaires de recherche du Canada (CRC)	Hypertension and vascular research.		75,171		
	SCHIFFRIN, Ernesto	Chaires de recherche du Canada (CRC)	Hypertension and vascular research.		100,137		
	SCHIFFRIN, Ernesto	Regroupement de particuliers	Rodent phenotyping facility.	781			
	SCHIFFRIN, Ernesto	Juvenile Diabetes Research Foundation International	Nox-derived Rox: Renal and vascular complications of type 1 diabetes.	14,754			
	SCHIFFRIN, Ernesto	Regroupement de particuliers	Cardiohypertension research "Fonds d'urgence".	40,000			
	SCHIFFRIN, Ernesto	Instituts de recherche en santé du Canada (IRSC)	MicroRNAs and gene regulation on vascular remodeling in hypertension from mice to humans.	123,293			
	SCHIFFRIN, Ernesto	Instituts de recherche en santé du Canada (IRSC)	T-regulatory cells and vascular injury in hypertension	142,230			
	SCHIFFRIN, Ernesto	Instituts de recherche en santé du Canada (IRSC)	Endothelin, vascular inflammation and injury, and hypertension.	149,170			
	SCHIPPER, Hyman Morris	National Institutes of Health (NIH) (USA)	Clinical assessment of patients with AD and NEC individuals.	89,774			
	SCHIPPER, Hyman Morris	Research Foundation Sir Mortimer B. Davis, Jewish General Hospital	Mary Katz Claman Foundation Funds.	146,018			
	SCHIPPER, Hyman Morris	Instituts de recherche en santé du Canada (IRSC)	Role of HO-1 in aging & Parkinsonian neural tissues III.	150,784			
	SMALL, David	Regroupement de particuliers	Pulmonary Oncology Staff.	3,000			
	SMALL, David	Regroupement de particuliers	Airway center.	15,000			
	SMALL, David	Regroupement de compagnies, corporations	Pulmonary Research.	26,400			
	SUISSA, Samy	Université McGill	James McGill Professor.		797		
	SUISSA, Samy	Université McGill	James McGill Professor.		797		
Khosrow-Khavar, Farzin	SUISSA, Samy	Fonds de la recherche en santé du Québec (FRSQ)	The use of stains and prevention of colorectal cancer-specific mortality.		1,566		
Khosrow-Khavar, Farzin	SUISSA, Samy	Sir Mortimer B. Davis - Hôpital Général Juif	The use of stains and prevention of colorectal cancer-specific mortality.		5,000		
	SUISSA, Samy	Université McGill	James McGill Professor.		9,203		
	SUISSA, Samy	Université McGill	James McGill Professor.		9,203		
Tascilar, Koray	SUISSA, Samy	Gouvernement de la Turquie	Cardiovascular risk prediction for primary prevention in patients with rheumatoid arthritis.		15,000		
WU, Jennifer	SUISSA, Samy	Instituts de recherche en santé du Canada (IRSC)	The use of insulin glargine and risk of colorectal cancer in patients with type 2 diabetes.		35,000		
	SUISSA, Samy	Université McGill	James McGill Professor.	1,195			
	SUISSA, Samy	Université McGill	James McGill Professor.	1,195			
Faillie, Jean-Luc	SUISSA, Samy	Société francophone du diabète (SFD)	Pharmacoépidémiologie et pharmacologie sociale des médicaments du diabète de type 2.	2,805			
	SUISSA, Samy	Instituts de recherche en santé du Canada (IRSC)	CIHR - Quebec Respiratory Health Training Program	8,125			
	SUISSA, Samy	Instituts de recherche en santé du Canada (IRSC)	Prince Edward Island Canadian Network for observational drug effect studies (CNODES) demonstration project.	8,505			
	SUISSA, Samy	Université McGill	James McGill Professor.	13,805			
	SUISSA, Samy	Université McGill	James McGill Professor.	13,805			
	SUISSA, Samy	Instituts de recherche en santé du Canada (IRSC)	Propensity scores and marginal structural models in drug safety research	28,150			
	SUISSA, Samy	Instituts de recherche en santé du Canada (IRSC)	Newfoundland and Labrador CNODES demonstration project.	116,465			
	SUISSA, Samy	Instituts de recherche en santé du Canada (IRSC)	Canadian Network for Observational Drug Effect Studies.	3,180,100			

	TAGALAKIS, Vicky	Instituts de recherche en santé du Canada (IRSC)	New oral anticoagulants for the prevention of venous thromboembolism in high-risk ambulatory cancer patients: A randomized placebo-controlled, double-blind clinical trial.	1,200		
	TAGALAKIS, Vicky	Fondation des Maladies du Coeur du Québec	Screening for occult malignancy in patients with unprovoked venous thromboembolism: a randomized controlled trial using a comprehensive computed tomography of the abdomen/pelvis (SOME trial).	4,945		
	TAGALAKIS, Vicky	Instituts de recherche en santé du Canada (IRSC)	The use of extended peri-operative low molecular weight heparin to improve cancer specific survival following surgical resection of colon cancer: A randomized controlled trial - PERIOP-01.	12,884		
	THERRIEN, Judith	Instituts de recherche en santé du Canada (IRSC)	The Canadian outcomes registry late after TEtralogy of fallot repair (CORRELATE).	1,000		
JEWETT, Lisa	THOMBS, Brett	Instituts de recherche en santé du Canada (IRSC)	Une intervention visant à réduire la détresse reliée à l'image corporelle chez les femmes avec défigurement causé par la sclérodermie		36	
KWAKKENBOS, Linda	THOMBS, Brett	Instituts de recherche en santé du Canada (IRSC)	Scleroderma patient-centered interventions network (SPIN).		254	
	THOMBS, Brett	Université McGill	William Dawson Scholar		1,195	
JEWETT, Lisa	THOMBS, Brett	Rare Disease Foundation (The)	Testing the feasibility of the changing faces practitioner training and induction program for scleroderma patients.		3,221	
LEVIS, Alexander	THOMBS, Brett	Instituts de recherche en santé du Canada (IRSC)	Assessing excess significance bias in randomized controlled trials of non-pharmacological interventions for pain management in rheumatic diseases.		5,000	
JEWETT, Lisa	THOMBS, Brett	Rheumatology Research Foundation	Health Professional Research Preceptorship.		5,500	
DELISLE, Vanessa	THOMBS, Brett	Rheumatology Research Foundation	Health Professional Research Preceptorship.		5,500	
JEWETT, Lisa	THOMBS, Brett	Conseil de Recherches en Sciences Naturelles et Génie du Canada (CRSNG)	Social anxiety from disfigurement due to medical illness: From assessment to intervention.		5,987	
MILETTE, Katherine	THOMBS, Brett	Instituts de recherche en santé du Canada (IRSC)	Barriers to depression screening in medical setting: Examining cumulative false-positive rates and possible solutions in rheumatology, oncology, and cardiovascular care settings.		12,355	
	THOMBS, Brett	Université McGill	William Dawson Scholar		13,805	
RAZYKOV, Ilya	THOMBS, Brett	Instituts de recherche en santé du Canada (IRSC)	Understanding suicidal thinking and risk in a chronic, progressive disease: From epidemiology to application.		14,615	
	THOMBS, Brett	Société de l'arthrite (La)	The Scleroderma patient-centred intervention Network (SPIN).		21,635	
KWAKKENBOS, Linda	THOMBS, Brett	Fonds de la recherche en santé du Québec (FRSQ)	La fatigue lié aux maladies chroniques dans la sclérodermie: de l'évaluation à l'intervention		30,000	
	THOMBS, Brett	Société de l'arthrite (La)	The Scleroderma patient-centred intervention Network (SPIN).		65,865	
JEWETT, Lisa	THOMBS, Brett	Instituts de recherche en santé du Canada (IRSC)	Social anxiety from disfigurement due to medical illness: From assessment to intervention.		70,000	
	THOMBS, Brett	Université McGill	William Dawson Scholar	797		
	THOMBS, Brett	Conseil de Recherches en Sciences Humaines du Canada (CRSH)	Searching for identity in the dark: The experiences of women living in rare and unpredictable disease.	6,234		
	THOMBS, Brett	Université McGill	William Dawson Scholar	9,203		
	THOMBS, Brett	Regroupement de particuliers	International Consortium for Behavioral/Educational/Psychological Interventions for Scleroderma. - SPIN COHORT NETWORK.	14,325		
	THOMBS, Brett	Instituts de recherche en santé du Canada (IRSC)	The Scleroderma patient-centered intervention network (SPIN) feasibility trial planning meeting.	14,629		
	THOMBS, Brett	Research Foundation Sir Mortimer B. Davis, Jewish General Hospital	International Consortium for Behavioral/Educational/Psychological Interventions for Scleroderma. - SPIN COHORT NETWORK.	50,000		
	THOMBS, Brett	Instituts de recherche en santé du Canada (IRSC)	Emerging Team: The Scleroderma patient-centered intervention Network.	299,958		
MCGEE, Shauna	TRIFIRO, Mark A	Université McGill	Dissecting and modeling networks for cancer cell survival.		1,692	
Mokhtar, Shaza	TRIFIRO, Mark A	Saudi Arabian Cultural Bureau in Canada	Understanding the molecular pathology of spinal and bulbar muscular atrophy by identifying genetic interactors of an AR-Humanized fly.		8,736	
MCGEE, Shauna	TRIFIRO, Mark A	Instituts de recherche en santé du Canada (IRSC)	Approche de la biologie des systèmes à l'hétérogénéité tumorale dans le cancer de la prostate		17,500	
	TRIFIRO, Mark A	Cancer de la prostate Canada	Novel targeting abiotic therapeutics and imaging agents for prostate cancer.	14,830		
	TRIFIRO, Mark A	Cancer de la prostate Canada	Androgen receptor-mediated translational regulation in prostate cancer.	21,548		
	TRIFIRO, Mark A	Cancer de la prostate Canada	Novel targeting abiotic therapeutics and imaging agents for prostate cancer.	44,995		

	TRIFIRO, Mark A	Jewish Hospital Foundation	Artificial pancreas research project.	50,000		
	TRIFIRO, Mark A	Jewish Hospital Foundation	Insulin pump center.	75,791		
	TRIFIRO, Mark A	Cancer de la prostate Canada	Androgen receptor-mediated translational regulation in prostate cancer.	79,139		
	TRIFIRO, Mark A	Instituts de recherche en santé du Canada (IRSC)	Innovative approaches to functional characterization of the androgen receptor in prostate cancer.	102,692		
	TRIFIRO, Mark A	Regroupement de particuliers	Endocrinology research and development.	136,683		
KHANASSOV, Vladimir	VEDEL, Isabelle	Fonds de la recherche en santé du Québec (FRSQ)	Gestion de cas pour les patients avec des troubles cognitifs en soins de santé primaires et communautaires: obstacles à l'implantation. Revues systématiques mixtes de la littérature		3,125	
	VEDEL, Isabelle	Fonds de la recherche en santé du Québec (FRSQ)	Maladie d'Alzheimer et multimorbidité : adapter et améliorer la qualité et l'efficacité des services de première ligne		9,452	
	VEDEL, Isabelle	Instituts de recherche en santé du Canada (IRSC)	Maladie d'Alzheimer: adapter et améliorer la qualité et l'efficacité des services de première ligne		45,000	
	VEDEL, Isabelle	Instituts de recherche en santé du Canada (IRSC)	Veilles et les maladies chroniques de RUIS McGill (Réseau Universitaire Intégré de Santé McGill).	569		
	VEDEL, Isabelle	Fonds de la recherche en santé du Québec (FRSQ)	Déterminants de la continuité des soins aux personnes âgées vulnérables inscrites auprès d'un médecin d'une unité de médecine familiale du Québec : une étude transversale.	800		
	VEDEL, Isabelle	Fonds de la recherche en santé du Québec (FRSQ)	Maladie d'Alzheimer et multimorbidité : adapter et améliorer la qualité et l'efficacité des services de première ligne	2,473		
	VEDEL, Isabelle	Fonds de la recherche en santé du Québec (FRSQ)	Maladie d'Alzheimer et multimorbidité : adapter et améliorer la qualité et l'efficacité des services de première ligne	7,527		
	VEDEL, Isabelle	Instituts de recherche en santé du Canada (IRSC)	Assessing care models implemented in primary health care for persons with Alzheimer's disease and related disorders	45,499		
	VEDEL, Isabelle	Research Foundation Sir Mortimer B. Davis, Jewish General Hospital	Start-Up Funds - Epidemiology	50,000		
	VEDEL, Isabelle	Fonds de recherche du Québec - Santé (FRQS)	Plan d'action ministériel sur les troubles cognitifs liés au vieillissement: une évaluation de l'implantation et des résultats des projets initiaux en vue d'une généralisation progressive au Québec.	77,546		
	VEDEL, Isabelle	Research Foundation Sir Mortimer B. Davis, Jewish General Hospital	Start-Up Funds - Epidemiology	130,000		
Liang, Jia Ming (Calvin)	WAINBERG, Mark A.	Université McGill	Effect of integrasi inhibitor, dolutegravir, on the molecular evolution.		582	
King, Stacey	WAINBERG, Mark A.	University of Liverpool (The) (UK)	Selection of HIV drug resistance against novel compounds.		1,033	
	WAINBERG, Mark A.	Université McGill	James McGill Professor.		1,195	
Cutillas, Vincent	WAINBERG, Mark A.	Instituts de recherche en santé du Canada (IRSC)	The addition of R262K to the H51Y mutation in HIV-1 subtype B integrase confers low-level resistance against dolutegravir.		1,500	
King, Stacey	WAINBERG, Mark A.	University of Liverpool (The) (UK)	Selection of HIV drug resistance against novel compounds.		1,997	
QUASHIE, Peter	WAINBERG, Mark A.	Instituts de recherche en santé du Canada (IRSC)	Drug resistance of HIV to second generation integrase inhibitors.		2,500	
ANSTETT, Kaitlin	WAINBERG, Mark A.	Université McGill	Investigating resistance phenotypes in HIV-1.		2,750	
SINGHROY, Diane	WAINBERG, Mark A.	Université McGill	The contribution of cellular PRMT6 to HIV-1 pathogenesis.		5,011	
Zanichelli, Veronica	WAINBERG, Mark A.	University of Padova	Studies on HIV drug resistance involving integrase inhibitors.		5,885	
ANSTETT, Kaitlin	WAINBERG, Mark A.	Instituts de recherche en santé du Canada (IRSC)	Investigating resistance phenotypes in HIV-1.		10,192	
DEPATUREAUX, Agnes	WAINBERG, Mark A.	Réseau Canadien pour les Essais VIH (Vancouver, B.C.)	HIV-1 group O integrase: Impact of genetic polymorphisms on integrase inhibitors resistance (IIs) and on enzymatic activity.		13,599	
	WAINBERG, Mark A.	Université McGill	James McGill Professor.		13,805	
HASSOUNAH, Said	WAINBERG, Mark A.	Fonds de la recherche en santé du Québec (FRSQ)	Validation de SIVmac239 comme un modèle primate non humain pour l'étude de la résistance du VIH aux inhibiteurs d'intégrase		16,703	
	WAINBERG, Mark A.	Université McGill	James McGill Professor.	797		
	WAINBERG, Mark A.	Université McGill	James McGill Professor.	9,203		
	WAINBERG, Mark A.	National Institutes of Health (NIH) (USA)	HIV Prevention Trial Network Leadership: Biomedical Sciences Committee Chair	9,667		
	WAINBERG, Mark A.	Canadian Foundation for AIDS Research (CANFAR)	Investigating the role of subtype-specific polymorphisms in HIV-1 resistance to integrase inhibitors.	19,780		
	WAINBERG, Mark A.	Regroupement de compagnies, fondations et particuliers (Canada)	Québec Conference.	22,292		
	WAINBERG, Mark A.	Fonds de la recherche en santé du Québec (FRSQ)	SIDAMI-Surveillance de l'épidémie de résistance du VIH.	30,000		
	WAINBERG, Mark A.	Fonds de la recherche en santé du Québec (FRSQ)	Réseau SIDA et maladies infectieuses coordination	31,250		
	WAINBERG, Mark A.	Fonds de la recherche en santé du Québec (FRSQ)	SIDAMI-Banque de spécimens viraux/Traitement des échantillons	40,000		

	ASSOULINE, Sarit	Pharmacyclics	CRU - A multicenter, open-label, phase 2, safety and efficacy study of the Bruton's tyrosine kinase (Btk) inhibitor, pCI-32765, in subjects with relapsed or refractory de Novo diffuse large B-cell lymphoma.			10,921
	ASSOULINE, Sarit	Novartis Pharmaceuticals Corporation	CRU-A phase II multi-center, open, label, randomized study to assess safety and efficacy of two different schedules of oral LDE225 in adult patients with relapsed/refractory or untreated elderly patients with acute leukemia.			11,542
	ASSOULINE, Sarit	Millennium Pharmaceuticals Inc (Cambridge, MA, USA)	CRU - An open-label, dose-escalation, phase 1 study of MLN9708, a second-generation proteasome inhibitor, in adult patients with lymphoma.			13,128
	ASSOULINE, Sarit	Infinity Pharmaceuticals	CRU-A phase 2 study of IPI-145 in subjects with refractory indolent non-Hodgkin lymphoma.			13,578
	ASSOULINE, Sarit	Genzyme Corp.	CRU - A phase 3, randomized, double-blind, placebo-controlled, multi-center study confirming the efficacy and safety of Genz-112638 in patients with Gaucher Disease Type 1.			14,888
	ASSOULINE, Sarit	AbbVie	CRU - A phase 2 open-label study of efficacy of ABT-199 in subjects with relapsed or refractory chronic lymphocytic leukemia harboring the 17p deletion.			21,060
	ASSOULINE, Sarit	Hoffmann-La Roche Limitée, Canada	CRU-An adaptive, comparative, randomized, parallel-group, multi-center, phase Ib study of subcutaneous (SD) rituximab versus intravenous rituximab both in combination with chemotherapy (fludarabine and cyclophosphamide), in patients with previously untreated...			21,240
	ASSOULINE, Sarit	Onyx Industries Inc.	CRU - A randomized, multicenter, phase 3 study comparing carfilzomib, lenalidomide, and dexamethasone (CRd) vs. lenalidomide and dexamethasone (Rd) in subjects with relapsed multiple myeloma.			27,809
	ASSOULINE, Sarit	Hoffmann-La Roche Limitée, Canada	CRU-GO28852-A phase IB/II study, to evaluate the safety and efficacy of vismodegib in relapsed/refractory acute myelogenous leukemia (AML) and relapsed/refractory high-risk myelodysplastic syndrome (MDS).			29,300
	ASSOULINE, Sarit	Quintiles Inc. (USA)	CRU-A multicenter, phase III, open-label, randomized study in relapsed/refractory patients with chronic lymphocytic leukemia to evaluate the benefit of GDC-0199 (ABT-199) plus rituximab compared with bendamustine plus rituximab.			29,567
	ASSOULINE, Sarit	Genentech Inc..	CRU - A randomized, open-label, multicenter, phase II trial evaluating the safety and activity of DCDT2980S in combination with rituximab or DCDS4501A in combination with rituximab in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.			37,301
	ASSOULINE, Sarit	Hoffmann-La Roche Limitée, Canada	CRU - A multi center, open-label, phase 1/1b study of escalating doses of RO5503781 administered orally as a single agent or in combination with cytarabine in patients with acute myelogenous leukemia (AML)			39,700
	ASSOULINE, Sarit	Bristol-Myers Squibb Canada Inc.	CRU-A single-arm, open-label, phase 2 study of Nivolumab (BMS-936558) in subjects with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after failure of autologous stem cell transplant (ASCT) or after failure of at least two prior multi-agent			44,085
	ASSOULINE, Sarit	Gilead Sciences	CRU-A Phase 2 open-label study evaluating the efficacy, safety, tolerability, and pharmacodynamics of GS9973 in subjects with relapsed or refractory hematologic malignancies.			104,014
	ASSOULINE, Sarit	Medimmune Inc.	CRU-A phase 2 open-label study of MEDI-551 and Bendamustine vs Rituximab and Bendamustine in adults with relapsed or refractory CLL.			141,690
	ASSOULINE, Sarit	Genentech Inc..	CRU-An open-label, multicenter, randomized, phase III study to investigate the efficacy and safety of bendamustine compared with bendamustine + RO5072759 (GA101) in patients with rituximab-refractory, indolent non-hodgkin's lymphoma.			273,459
	BARON, Murray	JSS Recherche médicale	A Canadian randomized controlled trial (RCT) of real world Cimzia treatment in RA: Randomizing to stop vs continued DMARDs.			323
	BARON, Murray	Abbott Laboratories	Real life evaluation of rheumatoid arthritis in Canadians taking HUMIRA.			1,800
	BARON, Murray	Hoffmann-La Roche Limitée, Canada	A Phase II/III, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of tocilizumab versus placebo in patients with systemic sclerosis.			15,583
	BARON, Murray	Mount Sinai Hospital	The Canadian ArTHritis CoHort (CATCH): A prospective cohort study of adults with new-onset inflammatory arthritis symptoms.			19,625
	BATIST, Gerald	Sunshine Biopharma Inc	A biomarker-driven therapy in the age of personalized cancer medicine.			0

	BATIST, Gerald	AstraZeneca Canada Inc.	CRU-A phase I, open-label, multicenter study to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumour activity of ascending doses of AZD5363 under adaptable dosing schedules in patients with advanced solid malignancies.			147,118
	BLOSTEIN, Mark	Glaxo Smith Kline	Treatment of thrombocytopenia with eltrombopag or intravenous immune globulin (IVIg) before and during invasive procedures in patients with immune thrombocytopenia - BRIDGING ITP study.			3,816
	BLOSTEIN, Mark	Sanofi-Aventis (Canada)	ENOXA_L_02260-VTE Registry - National, prospective, observational cohort study of venous thrombembolism management with the low molecular weight heparin, enoxaparin, in the outpatient setting in Canada.			27,000
	BLOSTEIN, Mark	Boehringer Ingelheim (Canada) Ltd	A phase III, case series clinical study of the reversal of the anticoagulant effects of dabigatran by intravenous administration of 5.0g idarucizumab (BI 655075) in patients treated with dabigatranetexilate who have uncontrolled bleeding			39,542
	CHERTKOW, Howard	Merck Frosst Canada Inc	A randomized, placebo controlled, parallel-group, double-blind efficacy and safety trial of MK-8931 in subjects with mild to moderate Alzheimer's disease.			3,000
	CHERTKOW, Howard	Abbott Laboratories	A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of ABT-126 in subjects with mild-to-moderate Alzheimer's Disease on stable doses of acetylcholinesterase inhibitors.			37,386
	CHERTKOW, Howard	TauRx Therapeutics Ltd.	Randomized, double-blind, placebo-controlled, parallel-group, 18-month safety and efficacy study of leuco-methylthioninium bis(hydromethanesulfonate) in subjects with mild Alzheimer's disease.			48,962
	COHEN, Albert	Robarts Research Institute (formerly John P. Robarts Research Institute)	A 52 week randomised, double-blind, placebo-controlled study to investigate the efficacy and safety of GSK1605786A in the maintenance of remission in subjects with Crohn's disease.			2,548
	COHEN, Albert	Abbott Laboratories	M10-223 - A multicenter, open-label study of the human anti-TNF monoclonal antibody adalimumab to evaluate the long term safety and tolerability of repeated administration of adalimumab in subjects with ulcerative colitis.			3,833
	COHEN, Albert	Robarts Research Institute (formerly John P. Robarts Research Institute)	An open-label extension study to assess the safety of GSK1605786A in subjects with Crohn's disease.			5,017
	COHEN, Albert	Quintiles Canada Inc.	A phase 3, open-label study to determine the long-term safety and efficacy of MLN002 in patients with ulcerative colitis and Crohn's disease.			11,995
	COHEN, Victor	Boehringer Ingelheim (Canada) Ltd	An open label trial of afatinib in treatment-naive or chemotherapy pre-treated patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR mutation(s).			10,009
	COHEN, Victor	Astellas Pharma Inc.	A randomized, double-blind, phase 2 study of erlotinib (Tarceva) in combination with OSI-906 or placebo in chemo-naive patients with advanced NSCLC with activating mutations of the epidermal growth factor receptor (EGFR) gene.			13,349
	COHEN, Victor	Pharmaceutical Research Associates Inc.	A multi-center phase III randomized, double-blind placebo-controlled study of the cancer vaccine Stimuvax (L-BLP25 or BLP25 liposome vaccine) in non-small cell lung cancer (NSCLC) subjects with unresectable stage III disease.			15,788
	COHEN, Victor	Hoffmann-La Roche Limitée, Canada	Poplar: A phase II, open-label, multicenter, randomized study to investigate the efficacy and safety of MPDL3280A (ANTI-PD-L1 ANTIBODY) compared with docetaxel in patients with non-small cell lung cancer after platinum failure.			30,500
	COHEN, Victor	Hoffmann-La Roche Limitée, Canada	OAK-A phase III, open-label, multicenter, randomized study to investigate the efficacy and safety of MPDL3280A (Anti-PD-L1 antibody) compared with docetaxel in patients with non-small cell lung cancer after failure with platinum-containing chemotherapy.			33,844
	DASCAL, André	Medpace Inc.	A phase II, randomized, double-blind, active-controlled clinical study to investigate the efficacy and safety of SMT19969 (200mg BID) for 10 days compared with vancomycin (125mg QID) for 10 days for the treatment of			3,856
	EISENBERG, Mark	Pfizer Canada Inc.	GA3041Z4-Evaluation of Varenicline-(Champix™) in smoking cessation for patients post-acute coronary syndrome (EVITA) trial.			30,000
	FALLAVOLLITA, Sabrina	JSS Recherche médicale	Prospective observational study to evaluate the use of musculoskeletal ultrasonography to improve rheumatoid arthritis management: Canadian experience (Echo Study).			2,340
	FALLAVOLLITA, Sabrina	Abbott Laboratories Ltd	Drug HUMIRA.			4,100

	FERRARIO, Cristiano	Celldex Therapeutics	A randomized multicenter pivotal study of CDX-011 (CRO11-vcMMAE) in patients with metastatic, GPNMB over-expressing, triple-negative breast cancer.			9,429
	FERRARIO, Cristiano	Bristol-Myers Squibb Canada Inc./Novartis Pharma Canada Inc.	A phase II randomized, double-blind placebo controlled, study of letrozole with or without BYL719 or buparlisib, for the neoadjuvant treatment of postmenopausal women with hormone receptor-positive HER2-negative breast cancer.			10,438
	FERRARIO, Cristiano	Hoffmann-La Roche Limitée, Canada	CRU - A phase II, multicenter, single-arm study of MDPL3280A in patients with locally advanced or metastatic urothelial bladder cancer.			47,154
	FERRARIO, Cristiano	Scimega Recherche	CRU - A phase 1b, open-label study to assess the safety and tolerability of ONT-380 combined with ado-trastuzumab emtansine (T-DM1).			52,637
	GREENAWAY, Christina	Sanofi Pasteur Inc. (USA)	Efficacy, immunogenicity and safety study of clostridium difficile toxoid vaccine in subjects at risk for C. difficile infection.			84,265
	GYGER, Martin	Celgene Corporation	CRU-A phase 3, multicenter, randomized, open-label Study to Compare the Efficacy and Safety of Pomalidomide in Combination with Low-Dose Dexamethasone versus High-Dose Dexamethasone in Subjects with Refractory or Relapsed and Refractory Multiple Myeloma.			3,304
	GYGER, Martin	Celgene Corporation	CRU-Companion Study: Open-Label, Multi-Center, Single-Arm Study for the Safety and Efficacy of Pomalidome (CC-4047) Monotherapy for Subjects with Refractory or Relapsed and refractory Multiple Myeloma.			4,389
	GYGER, Martin	Celgene Corporation	CRU-A multicenter, single-arm, open-label treatment use program for pomalidomide (POM in combination with low dose dexamethasone (Ld-Dex) in subjects with relapses or refractory multiple myeloma.			15,842
	HILZENRAT, Nir	Janssen Pharmaceutica Inc	A Canadian retrospective registry to examine real world effectiveness, safety, patient characteristics, and healthcare management across various practice settings in HCV-infected patients who initiated treatment with simeprevir.			1,500
	HILZENRAT, Nir	Bristol-Myers Squibb Canada Inc.	A phase 3 study with Asunaprevir and Declatasvir (DUAL) for null or partial responders to peginterferon alfa-2a and ribavirin (P/R), intolerant or ineligible to P/R subjects and treatment naive subjects with chronic hepatitis C genotype 1b infection.			8,105
	HILZENRAT, Nir	AbbVie	An international multicenter prospective observational study to evaluate the epidemiology, humanistic and economic outcomes of treatment for chronic hepatitis C virus (HCV) MOSAIC.			8,535
	HIRSCH, Andrew	Bayer Canada Inc.	Long-term extension, multi-centre, multi-national study to evaluate the safety and tolerability of oral BAY 63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg tid) in patients with chronic thromboembolic pulmonary arterial hypertension.			2,604
	HIRSCH, Andrew	Bayer Canada Inc.	An open-label phase IIIb study of riociguat in patients with in-operable CTEPH, or recurrent or persisting pulmonary hypertension (PH) after surgical treatment who are not satisfactory treated and cannot participate in any other CTEPH trial.			8,561
	HUDSON, Marie	JSS Recherche médicale	Prospective observational study to evaluate the use of musculoskeletal ultrasonography to improve rheumatoid arthritis management: Canadian experience (Echo Study).			2,918
	HUDSON, Marie	Janssen Pharmaceutica Inc	Health-related quality of life (HRQoL) across systematic autoimmune rheumatic diseases (SARD).			17,361
	KAHN, Susan Rebecca	Lawson Health Research Institute	A prospective study of upper extremity deep vein thrombosis to determine the prevalence of post-thrombotic syndrome in patients managed with anticoagulation.			1,250
	KAHN, Susan Rebecca	Bayer (Canada) Inc.	Reduced-dosed rivaroxaban and standard-dosed rivaroxaban versus ASA in the long-term prevention of recurrent symptomatic venous thromboembolism (VTE) in patients with symptomatic deep-vein thrombosis and/or pulmonary embolism (Study 16416).			5,750
	KAHN, Susan Rebecca	Biomérieux Canada Inc.	REVERSE-REcurrent VEnous thromboembolism risk stratification evaluation II: Validation of the "Men and HERD002" - A clinical decision rule to identify patients with "Unprovoked" venous thromboembolism who can discontinue anticoagulants after six months of			6,000
	KAHN, Susan Rebecca	Daiichi Pharmaceutical Corporation	A randomized, open-label, parallel-group, multi-center study for the evaluation of efficacy & safety of edoxaban monotherapy versus (LMW) heparin/warfarin in subjects with symptomatic deep-vein thrombosis - edoxaban thrombus reduction imaging study (eTRIS)			12,199

	KAHN, Susan Rebecca	Portola Pharmaceuticals, Inc. (USA)	Multicenter, randomized, active-controlled efficacy and safety study comparing extended duration betrixaban with standard of care enoxaparin for the prevention of venous thromboembolism in acute medically ill patients.			45,484	
	KARAPLIS, Andrew C.	Amgen Canada Inc (Mississauga, Ont)	Prospective observational study to evaluate persistence with Prolia (denosumab) in postmenopausal women with osteoporosis in routine clinical practice.			3,546	
	KARAPLIS, Andrew C.	Eli Lilly Canada Inc.	Teriparatide and risedronate in the treatment of patients with severe postmenopausal osteoporosis: Comparative effects on vertebral fractures.			10,172	
	KARAPLIS, Andrew C.	Amgen Canada Inc (Mississauga, Ont)	A multi-center, international, randomized, double-blind, alendronate-controlled study to determine the efficacy and safety of AMG785 in the treatment of postmenopausal women with osteoporosis.			24,218	
	KAVAN, Petr	Amgen Canada Inc (Mississauga, Ont)	A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Pegfilgrastim Administered to Subjects With Newly DX, Locally-Advanced or Metastatic Colorectal Cancer Treated With Bevacizumab and Either 5-Fluorouracil, Oxaliplatin, Leucovorin (Folfox) or			191	
	KAVAN, Petr	Genentech Inc..	A Randomized, Double Blind, Placebo Controlled, Multicenter Phase II Study Evaluating the Efficacy and Safety of Onartuzuabm (MetMab) in Combination with Bevacizumab or Onartuzumab Monotherapy in Patients with Recurrent Glioblastoma			549	
	KAVAN, Petr	Eisai Inc. (New Jersey)	A Multicenter, Randomized, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-Line Treatment of Subjects With Unresectable Hepatocellular Carcinoma			1,097	
	KAVAN, Petr	Oncozyme Pharma Inc.	CRU - A phase II clinical study using Pentamidine in patients with metastatic cancer undergoing standard chemotherapy (mFOLFOX6 or FOLFIRI) as second-line treatment.			1,891	
	KAVAN, Petr	Sanofi-Aventis (Canada)	A Randomised Phase III Study of Capecitabine or 5-Fluorouracil-Based Regimen with or without Oxaliplatin as 2nd Line Treatment of Advanced or Metastatic Pancreatic Cancer in Patients Who Have received Gemcitabine-Based Chemotherapy			1,964	
	KAVAN, Petr	Hoffmann-La Roche Limitée, Canada	A randomized, phase III, multicenter, double-blind, placebo-controlled study evaluating the efficacy and safety of onartuzumab (metmab) in combination with 5-fluorouracil, folinic acid, and oxaliplatin (MFOLFOX6) in patients with metastatic HER2-negative,			2,848	
	KAVAN, Petr	Bristol-Myers Squibb Canada Inc. Novartis Pharma Canada Inc.	CRU - A phase Ib/II multi-center, open-label, dose escalation study of LGX818 and cetuximab or LGX818, BYL719, and cetuximab in patients with BRAF mutant metastatic colorectal cancer.			3,127	
	KAVAN, Petr	Amgen Canada Inc (Mississauga, Ont)	A retrospective observational study to estimate the attrition of patients across lines of systemic treatment for metastatic colorectal cancer in Canada.			3,260	
	KAVAN, Petr	Boehringer Ingelheim (Canada) Ltd	A double-blind, randomized, placebo controlled phase III study of nintedanib plus best supportive care (BSC) versus placebo plus BSC in patients with metastatic colorectal cancer refractory to standard therapies			4,089	
	KAVAN, Petr	Boehringer Ingelheim (Canada) Ltd	BIBW 2992 WITH OR WITHOUT DAILY TEMOZOLOMIDE IN THE TREATMENT OF PATIENTS WITH RECURRENT MALIGNANT GLIOMA			6,005	
	KAVAN, Petr	Sanofi-Aventis (Canada)	A Multicenter, Single arm, Open Label Clinical Trial to Evaluate the Safety and Health-Related Quality of Life of Aflibercept in Patients with Metastatic Colorectal Cancer (mCRC) Previously Treated with an Oxaliplatin-Containing Regimen, McG1308			17,040	
	LANGLEBEN, David	Actelion Pharmaceuticals Canada Inc.	A prospective, multicenter, double-blind, randomized, placebo-controlled, parallel-group, 12-week study to evaluate the safety and tolerability of macitentan in subjects with combined pre-and post-capillary pulmonary hypertension (CpcPH) due to left			5,800	
	LANGLEBEN, David	Bayer Canada Inc.	An open-label phase IIIb study of riociguat in patients with in-operable CTEPH, or recurrent or persisting pulmonary hypertension (PH) after surgical treatment who are not satisfactory treated and cannot participate in any other CTEPH trial.			9,218	
	LANGLEBEN, David	Actelion Pharmaceuticals Canada Inc.	AC-065A303: Long-term single-arm open-label study, to assess the safety and tolerability of Act-293987 in patients with pulmonary arterial hypertension.			9,802	

	LANGLEBEN, David	Actelion Pharmaceuticals Canada Inc.	A multicenter, double-blind placebo-controlled phase 3 study to demonstrate the efficacy and safety of ACT-293987 in patients with pulmonary arterial hypertension.			11,000	
	LANGLEBEN, David	Institut de Cardiologie de Montréal (ICM)	Phase-II study of the use of PulmoBind for molecular imaging of pulmonary hypertension.			60,500	
	LONGTIN, Yves	Agence de santé publique du Canada (ASPC)	Vancomycin-resistant enterococci (VRE) occurrence report protocol Canadian nosocomial infection surveillance program (CNISP).			34,395	
	MICHEL, Caroline	Bayer Canada Inc.	A randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the hemodynamic effects of rociquat (BAY 63-2521) as well as study & kinetics in patients with pulmonary hypertension associated with left ventricular...			22,547	
	MICHEL, Caroline	Aventis Pharma	Heart failure clinic equipment donation.			153,000	
	MILLER, Mark A.	Merck Frosst Canada Inc	A phase III, randomized, double-blind, placebo-controlled, adaptive design study of the efficacy, safety, and tolerability of a single infusion of MK-3415 (human monoclonal antibody to Clostridium difficile toxin A).			1,322	
	MILLER, Mark A.	Merck Frosst Canada Inc	A phase III, double-blind, randomized, placebo-controlled, multicenter clinical trial to study the safety, tolerability, efficacy, and immunogenicity of V212 in recipients of autologous hematopoietic cell transplants (HCTs).			6,629	
	MILLER, Wilson	MethylGene Inc.	CRU - Open-label dose-escalation trial to evaluate the safety, pharmacokinetics, and pharmacodynamics of daily oral MGCD265 administered without interruption to subjects with advanced malignancies.			2	
	MILLER, Wilson	Glaxo Smith Kline	CRU - VEG108844 - A study of Pazopanib versus Sunitinib in the treatment of subjects with locally advanced and/or metastatic renal cell carcinoma.			860	
	MILLER, Wilson	Hoffmann-La Roche Limitée, Canada	CRU - A multi-center, open-label, first-in-human, phase I dose-escalation study of single agent RO5503781, a small molecule MDM2 antagonist, administered orally in patients with advanced malignancies, except leukemia. Protocol no NP27872.			1,500	
	MILLER, Wilson	Glaxo Smith Kline	CRU - A rollover study to provide continued treatment with GSK2118436 to subjects with BRAF mutation-positive tumors.			2,800	
	MILLER, Wilson	Astellas Pharma Canada, Inc.	CRU - A phase I, open-label, multi-center study to assess the safety, pharmacokinetics and effectiveness of AGS-116C3F monotherapy in subjects with renal cell carcinoma of clear cell or papillary histology.			4,868	
	MILLER, Wilson	Amgen Canada Inc (Mississauga, Ont)	CRU-A phase 2, multicenter, single-arm trial to evaluate the biodistribution and shedding of talimogene laherparepvec in subjects with unresected, stage IIIb to IVM1a melanoma.			7,050	
	MILLER, Wilson	Bristol-Myers Squibb Canada Inc.	CRU - A randomized, open-label, phase 3 study of BMS-936558 vs. everolimus in subjects with advanced or metastatic clear-cell renal cell carcinoma who have received prior anti-angiogenic therapy.			8,668	
	MILLER, Wilson	Medpace Inc.	CRU - An international phase 3 randomized trial of autologous dendritic cell immunotherapy (AGS 003) plus standard treatment of advanced renal cell carcinoma (ADAPT).			12,526	
	MILLER, Wilson	Glaxo Smith Kline	CRU - BRF113683: a phase III randomized, open-label study comparing GSK2118436 to DTIC in previously untreated subjects with BRAF mutation positive advanced (stage III) or metastatic (stage IV) melanoma.			14,891	
	MILLER, Wilson	Novartis Pharmaceuticals Corporation	CRU - A phase Ib/II, multicenter, study of LEE011 in combination with lgx818 in adult patients with BRAF mutant melanoma.			36,208	
	MILLER, Wilson	Novartis Pharmaceuticals Corporation	CRU-CLGX818X2109 - The LOGIC 2 Trial - A phase II, multi-center, open-label study of sequential LGX818/MEK162 combination followed by a rational combination with targeted agents after progression, to overcome resistance in adult patients with locally			58,426	
	MILLER, Wilson	Hoffmann-La Roche Limitée, Canada	CRU-A multiple-center, open-label clinical pharmacology study with RO5503781 an MDM2 antagonist, in patients with solid tumors to determine: Part 1- One-sequence, 2-period crossover design to investigate the effect of posaconazole, a strong CYP3A4 inhibitor			111,500	
	MILLER, Wilson	Bristol-Myers Squibb Canada Inc.	CRU - CA209-037: A randomized, open-label phase III trial of BMS-936558 versus investigator's choice in advanced (unresectable or metastatic) melanoma patients progressing post anti-CTLA-4b therapy.			137,120	
	MILLER, Wilson	Bristol-Myers Squibb Canada Inc. Novartis Pharma Canada Inc.	CRU - A phase Ib/II, multicenter, open-label, dose escalation study of LGX818 in combination with MEK162 in adult patients with BRAF V600-dependent advanced solid tumors.			229,917	

	MILLER, Wilson	Merck Frosst Canada Inc	CRU-A multicenter, randomized, controlled, three-arm, phase III study to evaluate the safety and efficacy of two dosing schedules of MK-3475 compared to ipilimumab in patients with advanced melanoma.			462,907
	UGHTON, Matthew	IntelligentMDx (IMDx)	Contract for the selection of clinical specimens.			7,510
	POLLAK, Michael	Teva Pharma Industries CDA	CRU - A randomized phase 3 comparing standard first-line Docetaxel/Prednisone to Docetaxel/Prednisone in combination with Custirsen (OGX-011) in men with metastatic castrate resistant prostate cancer.			11,038
	POLLAK, Michael	Hanall Biopharma	The study involves in vitro and in vivo assays and no human participants are to be involved in the study and characterization of novel biguanides.			30,000
	RICHARDS, Brent	King's College London	Standard operating procedures.			8,307
	RICHARDS, Brent	Glaxo Smith Kline	Repitching existing therapies to new diseases.			48,323
	RICHARDS, Brent	Eli Lilly Canada Inc.	Collaborative Agreement.			111,610
	RUDSKI, Lawrence	Canadian Heart Research Center	Acute coronary syndromes quality enhancement research initiative III. ACS III QuERI.			2,000
	RUDSKI, Lawrence	Genzyme Canada	Prevalence of Anderson-fabry disease (AFD) in multiple high risk populations in a single hospital-based setting.			19,245
	SCHIFFRIN, Ernesto	Institut Servier (L') (France)	Gene expression profile in small resistance arteries in patients with hypertension with or without nephroangiosclerosis and its relation to small and large artery function and remodeling.			314,978
	SCHIPPER, Hyman Morris	Immunotec Recherche	Immunocal Prophylaxis in the GFAP.HMOX1 mouse model of neurodevelopmental and neurodegenerative disorders - Phase 1 and Phase 2.			47,617
	SHEPPARD, Richard	Bristol-Myers Squibb Canada Inc. Novartis Pharma Canada Inc.	A multicenter, randomized, double-blind, parallel-group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared to enalapril on morbidity and mortality in patients with chronic heart failure and reduced injection fraction.			2,425
	SHEPPARD, Richard	Janssen Pharmaceutica Inc	A randomized, double-blind, event-driven, multicenter study comparing the efficacy and safety of oral Rivaroxaban with placebo for reducing the risk of death, myocardial infarction or stroke in subjects with chronic heart failure and significant coronary			4,000
	SHEPPARD, Richard	bioMérieux sa (France)	Galectin-3 as an early and sensitive marker for anthracyclines (with or without Trastuzumab) and Tyrosine kinase inhibitor induced cardiotoxicity			17,038
	SHEPPARD, Richard	Bayer Canada Inc.	A randomized, double-blind, double-dummy, multi-center study to assess safety and efficacy of BAY-94-8862 in subjects with emergency presentation at the hospital because of worsening chronic heart failure with left ventricular systolic dysfunction and			44,448
	SIRHAN, Shireen	YM BioSciences Inc.	CRU - A phase II, open-label extension study evaluating the long-term safety, tolerability and efficacy of orally-administered CYT387 in primary myelofibrosis or post-polycythemia vera or post-essential thrombocythemia myelofibrosis (CCL09101E).			2,422
	SIRHAN, Shireen	INC Research	CRU - An open-label, multiple simon 2-stage study of INCB039110 administered orally to subjects with primary myelofibrosis (PMF), post polycythemia vera-myelofibrosis (PPVMF) or post essential thrombocythemia-myelofibrosis (PET-MF).			7,302
	SIRHAN, Shireen	Sanofi-Aventis (Canada)	CRU-ARD12042-A randomized phase II, open-label study of the efficacy and safety of orally administered SAR302503 in patients with polycythemia vera (PV) or essential thrombocythemia (ET) who are resistant or intolerant to hydroxyurea.			9,705
	SIRHAN, Shireen	Gilead Sciences	CRU-A phase 2, open-label, randomized study to evaluate the safety and efficacy of momelotinib in subjects with plicythemia vera or essential thrombocythemia.			9,800
	SIRHAN, Shireen	Gilead Sciences	CRU-Open-label study to assess the long-term safety and efficacy of momelotinib in subjects with primary myelofibrosis, post-polycythemia vera myelofibrosis, post-essential thrombocythemia myelofibrosis, polycythemia vera or essential thrombocythemi.			29,926
	TERRIEN, Judith	Hamilton Health Sciences	BAV - Beta-blockers and angiotensin receptor blockers in bicuspid aortic valve aortopathy.			7,465
	TRIFIRO, Mark A	Bristol-Myers Squibb Canada Inc.	A double-blind placebo-controlled, randomized, two stage, parallel-group, adaptive design phase 2a study to evaluate the effects of BMS-813160 in subjects with type 2 diabetes mellitus			10,300
	TRIFIRO, Mark A	Genome Prairie	Total utilization flax genomics (TUFGEN).			15,000

	VAITEKUNAS, Susan	Servier Canada Inc	Efficacy and safety of 3 doses of S 38093(2,5 and 20 mg/day) versus placebo in co-administration with donepezil (10 mg/day) in patients with moderate Alzheimer's Disease. A 24-week international, multi-centre, randomised, double-blind, placebo-controlled			251	
	WAINBERG, Mark A.	Merck Sharp & Dohme Research Laboratory	Part 1: Impact of subtype-specific variability on the effectiveness of integrase inhibitor.			158,008	
	Clinical Research Awards						
	Chen-Tournoux, A	Department of Medicine, JGH	Echocardiographic quantification of epicardial fat and its implications for cardiovascular risk				12,000
	Cohen, A	Department of Medicine, JGH	Inflammatory bowel disease rapid access clinic				12,000
	Dascal, A	Department of Medicine, JGH	Microbiome Replenishment Strategies to Treat and Protect against C difficile				4,000
	Galiatsatos, P	Department of Medicine, JGH	Impact of Lynch syndrome on career pursuits, professional development, and academic studies				12,000
	Greenaway, C.	Department of Medicine, JGH	The Burden of Viral Hepatitis in Migrants: A Population based Study				12,000
	Joyal, D	Department of Medicine, JGH	Novel techniques in chronic total occlusions (CTO) recanalization				12,000
	Langleben, D	Department of Medicine, JGH	Assessment of recruitment of functional pulmonary microvascular surface area in the determination of exercise limitation in patients with pulmonary arterial hypertension				12,000
	Levinoff, E.	Department of Medicine, JGH	Cognitive Impairment and Post-operative Outcomes in Elderly Individuals				8,000
	Palayew, M.	Department of Medicine, JGH	The Airways Centre at the Jewish General Hospital: Aspects of care in COPD patients				4,000
	Roshdy, O.	Department of Medicine, JGH	Analysis of the direct growth inhibitory effect of ipilimumab on melanoma cells				4,000
	Rudski, L.	Department of Medicine, JGH	Echocardiography-based research on the right heart				12,000
	Saad, N.	Department of Medicine, JGH	Chronic Obstructive Pulmonary Disease (COPD) and Pulmonary Rehabilitation				8,000
	Schweitzer, M.	Department of Medicine, JGH	Niemann-Pick C1-like (NPC1L1) structure/function analysis in a family of disparate ezetimibe responders				12,000
	Sebag, I	Department of Medicine, JGH	Matrix-array imaging for real-time, three-dimensional echocardiography and evolving techniques in cardiac mechanics				12,000
	Szilagyi, A.	Department of Medicine, JGH	IBD Epidemiology: Relationships with Vitamin D and population lactase distributions				4,000
	Tagalakis, V.	Department of Medicine, JGH	Venous thrombosis: Epidemiology and Cancer				12,000
	Tamila, M	Department of Medicine, JGH	The role of oncogenic and epigenetic events in the prediction of invasiveness and aggressiveness of differentiated thyroid carcinoma				12,000
	Teltscher, M.	Department of Medicine, JGH	Fecal Microbiota Transplant for the Treatment of C Difficile Infection				8,000
	Therrien, J	Department of Medicine, JGH	Beta Blockers and Angiotensin Receptor Blockers in Bicuspid Aortic Valve Disease Aortopathy				12,000
	Wyse, J.	Department of Medicine, JGH	The value of Botox-A in Acute Radiation Proctitis				4,000
	TOTALS			27,568,152	2,927,850	4,174,821	188,000